

Publications of Department of Medicine in 2025

A. Refereed Papers Included in Science Citation Index:

- ¹: 表此篇文章以榮總之名義發表。
²: 表此篇文章以榮總及陽明之名義發表。
³: 表此篇文章為國外進修時之著作。
⁴: 表此篇文章之第一作者為本部其它科之醫師。
⁵: 表此篇文章之第一作者為本院其它部科或他院之醫師。
*: 為通訊作者
#: Equal contribution

Gastroenterology

1. ^{2,5}Celsa C, Cabibbo G, Fulgenzi CAM, Battaglia S, Enea M, Scheiner B, D'Alessio A, Manfredi GF, Stefanini B, Nishida N, Galle PR, Schulze K, Wege H, Ciccio R, Hsu WF, Vivaldi C, Wietharn B, Lin RPT, Pirozzi A, Pressiani T, Dalbeni A, Natola LA, Auriemma A, Rigamonti C, Burlone M, Parisi A, Huang YH, Lee PC, Ang C, Marron TU, Pinter M, Cheon J, Phen S, Singal AG, Gampa A, Pillai A, Roehlen N, Thimme R, Vogel A, Soror N, Ulahannan S, Sharma R, Sacerdoti D, Pirisi M, Rimassa L, Lin CY, Saeed A, Masi G, Schonlein M, von Felden J, Kudo M, Cortellini A, Chon HJ, Camma C*, Pinato DJ*. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment. *Hepatology* 2025;81(3):837-852. (IF:16.8)
2. ^{2,5}Chang CL, Chang CC*, Chuang CL, Hsu SJ*, Tsai MH*, Tsai CJ, Chang YY, Hou MC, Lee FY. The influences of antihistamine on liver fibrosis, vasoresponsiveness, and portosystemic shunting in bile duct-ligated cirrhotic rats. *J. Chin. Med. Assoc.* 2025;88(11):825-835. (IF:2.4)
3. ^{2,5}Chen HH*, Chen CH, Hou MC, Fu YC, Li LH, Chou CY, Yeh EC, Tsai MF, Chen CH, Yang HC, Huang YT, Liu YM, Wei CY, Su JP, Lin WJ, Wang EHF, Chiang CL, Jiang JK, Lee IH, Liang KH, Chen WS, Tsai HC, Lin SY, Chang FP, Ho HL, Yeh YC, Tseng WC, Lin MH, Chang HT, Tseng LM, Liang WY, Chen PCH, Hsieh YC, Chen YM, Hsiao TH, Lin CH, Chen YJ, Chen IC, Mao CL, Chang SJ, Chang YL, Liao YJ, Lai CH, Lee WJ, Tung H, Yen TT, Yen HC, Chen MY, Lin YC, Kao YT, Kao BZ, Lee JE, Chung CL, Liu JC, Chan P, Lin CH, Chen CH, Wu IC, Lin LC, Wang JW, Shih SL, Hsieh SW, Hung CH, Li WM, Yang CJ, Yang CS, Weng RH, Chen YC, Chang CP, Wu TH, Lin YC, Sheen YJ, Wang SH, Chen SP, Raben T, Widen E, Hsu S, Hsieh FJ, Ho DR, Huang YH, Yang CH, Huang YS, Chen YF, Wu HM, Tsai PH, Huang KG, Chien CY, Ho YL, Wu MS, Kao JH, Liu YB, Juang JM, Lin MH, Lin YH, Lee JY, Lu HJ, Lu CH, Feng AC, Liu JS, Chiang CP, Chu NF, Lin JC, Yeh YW, Meng E, Huang CY, Li CC, Wang TF, Su KY, Wang JK, Chen MH, Chen HF, Ma GC, Chang TY, Chiang FT, Chang HJ, Kao KJ, Hung CF, Tsai CY, Chen PY, Tsui K, Chen YT, Kwok PY, Sheu WHH, Yang SF, Liou JM, Wang JY, Chiou JF, Wu JY, Fann CSJ*. Population-specific

polygenic risk scores for people of Han Chinese ancestry. *Nature* 2025;():-. (IF:48.5)

4. ^{2,5}Chen MY, Fang YJ, Chen CC, Chen CH, Luo JC, Bair MJ, Chen PY, Chou CK, Lee JY, Yang TH, Yu JY, Kuo CC, Chiu MC, Chen CY, Shun CT, Hu WH, Tsai MH, Hsu YC, Tseng CH, Chang CY, Lin JW, El-Omar EM, Lee YC, Wu MS, Liou JM*, Taiwan Gastrointestinal Dis Helicobacter Consortium. Overall and Stratified Accuracies of H. pylori Serology Testing: A Multicenter Study of 8497 Screening-Naive Adults. *Helicobacter* 2025;30(5): e70074. (IF:4.3)
5. ²Chen YJ, Hou MC*, Yang TC, Lee PC, Lu HS, Huang HC, Huang YH, Luo JC. Primary Prophylaxis for High-Risk Varices in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus Delayed Hepatic Decompensation: A Retrospective, Propensity Score Matching Study. *J. HEPATOCELL. CARCINOMA* 2025;12:1057-1067. (IF:3.4)
6. ^{2,5}Chiang NJ, Lee JH, Chen MH, Chao Y, Su WC, Bai LY, Wu SY, Hsu CH, Shan YS, Li CP, Chen SH, Chung WP, Hao WH, Chen LT*, Lin CC*. Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors. *Oncologist* 2025;30(4): oyaf051. (IF:4.2)
7. ^{2,5}Choi WM, Yip TCF, Wong GLH, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Clark LJ, Jafry Z, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Lim YS*. Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study. *Clin. Gastroenterol Hepatol.* 2025;23(2): 310-320. (IF:12.2)
8. ^{2,5}Choudhury A, Kulkarni AV, Arora V, Soin AS, Dokmeci AK, Chowdhury A, Koshy A, Duseja A, Kumar A, Mishra AK, Patwa AK, Sood A, Roy A, Shukla A, Chan A, Krag A, Mukund A, Mandot A, Goel A, Butt AS, Sahney A, Shrestha A, Cardenas A, Di Giorgio A, Arora A, Anand AC, Dhawan A, Jindal A, Saraya A, Srivastava A, Kumar A, Kaewdech A, Pande A, Rastogi A, Valsan A, Goel A, Kumar A, Singal AK, Tanaka A, Coilly A, Singh A, Meena BL, Jagadisan B, Sharma BC, Lal BB, Eapen CE, Yaghi C, Kedarisetty CK, Kim CW, Panackel C, Yu C, Kalal CR, Bihari C, Huang CH, Vasishtha C, Jansen C, Strassburg C, Lin CY, Karvellas CJ, Lesmana CRA, Philips CA, Shawcross D, Kapoor D, Agrawal D, Payawal DA, Praharaj DL, Jothimani D, Song DS, Kim DJ, Kim DS, Duan ZP, Karim F, Durand F, Shiha GE, D'Amico G, Lau GK, Pati GK, Narro GEC, Lee GH, Adali G, Dhakal GP, Szabo G, Lin HC, Li H, Nair HK, Devarbhavi H, Tevethia H, Ghazinian H, Ilango H, Yu HL, Hasan I, Fernandez J, George J, Behari J, Fung J, Bajaj J, Benjamin J, Lai JC, Jia JD, Hu JH, Chen JJ, Hou JL, Yang JM, Chang J, Trebicka J, Kalf JC, Sollano JD, Varghese J, Arab JP, Li J, Reddy KR, Raja K, Panda K, Kajal K, Kumar K, Madan K, Kalista KF, Thanapirom K, Win KM, Suk KT, Devadas K, Lesmana LA, Kamani L, Premkumar M, Niriella MA, Al Mahtab M, Yuen MF, Sayed MH, Alla M, Wadhawan M, Sharma MK, Sahu M, Prasad M, Muthiah MD, Schulz M, Bajpai M, Reddy MS, Praktiknjo M, Yu ML, Prasad M, Sharma M, Elbasiony M, Eslam M, Azam MG, Rela M, Desai MS, Vij M, Mahmud N, Choudhary NS, Marannan

- NK, Ormeci N, Saraf N, Verma N, Nakayama N, Kawada N, Baatarkhuu O, Goyal O, Yokosuka O, Rao PN, Angeli P, Parikh P, Kamath PS, Thuluvath PJ, Lingohr P, Ranjan P, Bhangui P, Rath P, Sakhuja P, Puri P, Ning Q, Dhiman RK, Kumar R, Vijayaraghavan R, Khanna R, Maiwall R, Mohanka R, Moreau R, Gani RA, Loomba R, Mehtani R, Rajaram RB, Hamid SS, Palnitkar S, Lal S, Biswas S, Chirapongsathorn S, Agarwal S, Sachdeva S, Saigal S, Kumar SE, Violeta S, Singh SP, Mochida S, Mukewar S, Alam S, Lim SG, Alam S, Shalimar, Venishetty S, Sundaram SS, Shetty S, Bhatia S, Singh SA, Kottlilil S, Strasser S, Shasthry SM, Maung ST, Tan SS, Treeprasertsuk S, Asthana S, Manekeller S, Gupta S, Acharya SK, Sudhamshu KC, Maharshi S, Asrani S, Dadhich S, Taneja S, Giri S, Singh S, Chen T, Gupta T, Kanda T, Tanwandee T, Piratvishuth T, Spengler U, Prasad VGM, Midha V, Rakhmetova V, Arroyo V, Sood V, Kumar BRV, Wong VWS, Pamecha V, Singh V, Dayal VM, Saraswat VA, Kim WR, Jafri W, Gu WY, Jun WY, Qi XL, Chawla YK, Kim YJ, Shi Y, Abbas Z, Kumar G, Shiina S, Wei L, Omata M, Sarin SK*. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia. *Hepatol. Int.* 2025;19(1):- (IF:6.1)
9. ^{2,5}Deng FS, Lin MH, Huang CL, Wu CC*, Lu CL, Tsai YC*. Effects of *Lactococcus cremoris* PS133 in 5-Hydroxytryptophan-Induced Irritable Bowel Syndrome Model Rats. *Int. J. Mol. Sci.* 2025;26(6):- (IF:4.9)
 10. ^{2,5}Eslam M*, Fan JG, Yu ML, Wong VWS, Cua IH, Liu CJ, Tanwandee T, Gani R, Seto WK, Alam S, Young DY, Hamid S, Zheng MH, Kawaguchi T, Chan WK, Payawal D, Tan SS, Goh GBB, Strasser SI, Viet HD, Kao JH, Kim W, Kim SU, Keating SE, Yilmaz Y, Kamani L, Wang CC, Fouad Y, Abbas Z, Treeprasertsuk S, Thanapirom K, Al Mahtab M, Lkhagvaa U, Baatarkhuu O, Choudhury AK, Stedman CAM, Chowdhury A, Dokmeci AK, Wang FS, Lin HC, Huang JF, Howell J, Jia JD, Alborai M, Roberts SK, Yoneda M, Ghazinian H, Mirijanyan A, Nan YM, Lesmana CRA, Adams LA, Shiha G, Kumar M, Ormeci N, Wei L, Lau G, Omata M, Sarin SK*, George J. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. *Hepatol. Int.* 2025;19(2):261-301. (IF:6.1)
 11. ^{2,5}Gao WL, Chen HM*, Liu CY, Huang TH, Li CP, Hsu SJ, Lee PC, Lee KC. Effects of Auricular Acupressure on Fatigue, Sleep Quality, Physical Activity, and Quality of Life in Pancreatic Cancer Patients Undergoing Chemotherapy A Randomized Controlled Trial. *Cancer Nurs.* 2025;():-. (IF:2.5)
 12. ²Ho CT, Tan ECH, Su CW*. Correspondence to letter to the editor 2 on "Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma". *Clin. Mol. Hepatol.* 2025;31(1):- (IF:16.9)
 13. ^{2,5}Hong CM, Su TH, Hsu SJ, Tseng TC, Liu CH, Yang HC, Kao JH, Chen PJ, Cheng PN, Hung CH, Peng CY, Chen CH, Lin CY, Kuo HT, Lin HC, Huang YH, Chen CY, Lin CL, Tsai PC, Zeng YS, Dai CY, Chuang WL, Huang JF, Huang CF, Yeh ML, Yu ML, Liu CJ*. Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de

- novo liver complications in hepatitis C. *J. Formos. Med. Assoc.* 2025;124(12):1149-1156. (IF:2.5)
14. ²Huang HC, Chang CL, Hsu SJ, Chang CC*, Chuang CL, Luo JC, Hou MC, Lee FY. Time-restricted feeding attenuates hepatic inflammation and enhances muscular endurance of biliary cirrhotic rats. *Life Sci.* 2025;379: 123856. (IF:5.1)
15. ^{2,5}Hui RWH, Chiu KWH, Lee IC, Wang CL, Cheng HM, Lu JL, Mao XH, Yu SR, Lam LK, Mak LY, Cheung TT, Chia NH, Cheung CC, Kan WK, Wong TCL, Chan ACY, Huang YH, Yuen MF, Yu PLH*, Seto WK*. Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgery. *Hepatology* 2025;82(2):344-356. (IF:16.8)
16. ^{2,5}Hung YP, Huang YH*. Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution-Authors' Reply. *Aliment. Pharmacol. Ther.* 2025;61(4):714-715. (IF:6.7)
17. ^{2,5}Hung YP, Lee PC, Chang YH, Yang MH, Chiu CH, Chen MH, Lan KH, Lee IC, Hou MC, Chao Y, Huang YH*. Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic Areas. *Aliment. Pharmacol. Ther.* 2025;61(3):501-512. (IF:6.7)
18. ²Huo TI*, Ho SY. Developing a feasible classification model for surgical hepatocellular carcinoma: More questions than answers. *Hepatol. Res.* 2025;55(4):622-623. (IF:3.4)
19. ²Huo TI*, Ho SY. Developing a reliable prognostic nomogram for surgical hepatocellular carcinoma: unanswered questions. *Hepatol. Int.* 2025;19(4):970-971. (IF:6.1)
20. ²Huo TI*, Ho SY. Predicting Late Tumor Recurrence in Surgical Hepatocellular Carcinoma: What Have We Missed?. *Ann. Surg. Oncol.* 2025;():-. (IF:3.5)
21. ²Huo TI*, Ho SY. Recompensation After TIPS for Patients With Advanced Cirrhosis: A New Way to Reverse the Outcomes?. *Liver Int.* 2025;45(4):-. (IF:5.2)
22. ^{2,5}Jang TY, Huang CF, Chang TS, Yang CC, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Kuo HT, Yu ML*. Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients-a nationwide Taiwan HCV registry. *J. Formos. Med. Assoc.* 2025;124(8):731-737. (IF:2.5)
23. ^{2,5}Kee KM, Chen CH, Liu TW, Huang YH, Hu JT, Chau GY, Chen KH, Chiang CJ, Lin CC, Hung CF, Wang TE, Huang SF, Ku HY, Huang BS, Ch'ang HJ, Tseng HP, Lu SN*. Secular trends and survival impact of high proportion of curative treatments for hepatocellular carcinoma in Taiwan, 2011-2019. *Ann. Hepatol.* 2025;30(2):-. (IF:4.4)

24. ²Lee IC, Lei HJ, Wang LC, Yeh YC, Chau GY, Hsia CY, Chou SC, Luo JC, Hou MC, Huang YH*. M2BPGi Correlated with Immunological Biomarkers and Further Stratified Recurrence Risk in Patients with Hepatocellular Carcinoma. *Liver Cancer* 2025;14(1):68-79. (IF:9.1)
25. ²Lee IC, Wang HW, Teng W, Lin TJ, Chen CH, Lai HC, Lee TY, Chang CW, Hung CH, Dai CY, Hung YP, Shen YC, Su CW, Ho MC, Lee WC, Chau GY, Ting CT, Liang PC, Liu CA, Chang PY, Chen KY, Lin SM, Chen LT, Huang YH*. Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma. *Clin. Mol. Hepatol.* 2025;31(4):- (IF:16.9)
26. ^{2,5}Lee JM, Tu CC, Fang CH, Lin SR, Wang SL, Lai WY, Tseng PW, Liao WE, Huang LY, Chao Y, Chen MH*. Detecting HER2-positive circulating tumor cells in gastric cancer using a flow cytometry-based approach. *Front. Med.* 2025;12():-. (IF:3)
27. ²Lee PC, Cheng TY, Ho CT, Huang KW, Chau GY, Huang YH, Huo TI, Hou MC, Wu JC, Su CW*. Gender Different Impacts of Muscle Mass and Adipose Tissue on Patients With Hepatocellular Carcinoma Undergoing Surgical Resection. *Liver Int.* 2025;45(2):- (IF:5.2)
28. ²Lee PC, Huang YH*. Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?. *Hepatology* 2025;():-. (IF:16.8)
29. ²Lee PC, Li PY, Lee CY, Lin SR, Wu CJ, Hung YW, Chen YH, Chan JW, Mon HC, Lee CJ, Chi CT, Lee IC, Hou MC, Chao Y, Huang YH*, Lee JM*. Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning. *BMC Cancer* 2025;25(1):- (IF:3.4)
30. ²Lee PC, Wu CJ, Hung YW, Lee CJ, Mon HC, Chi CT, Lee IC, Kuo YL, Chou SH, Luo JC, Hou MC, Huang YH*. Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy. *Hepatology* 2025 Jun 30. doi: 10.1097. (IF:16.8)
31. ²Lee PC, Wu CJ, Lee IC, Lee CJ, Hou MC, Huang YH*. Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapy. *JHEP Rep.* 2025;7(9): 101491. (IF:7.5)
32. ^{2,5}Lee SW*, Yang SS, Tsai PC, Huang CF, Chen CY, Hung CH, Chen CH, Tai CM, Cheng PN, Kuo HT, Tseng KC, Mo LR, Lo CC, Huang YH, Lin HC, Lee PL, Bair MJ, Chang TS, Lin CY, Wang SJ, Hsieh TY, Yang TH, Peng CY, Yang CC, Chong LW, Huang CW, Lin CW, Chu CH, Tsai MC, Kao JH, Liu CJ, Chuang WL, Lee TY, Yu ML*. Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nation-wide cohort study. *Clin. Mol. Hepatol.* 2025;31(3): 899-913. (IF:16.9)
33. ^{2,5}Li TH, Huang YS, Ma CC, Tsai SY, Tsai HC, Yeh HY, Shen HC, Hong SY, Su CW, Yang H, Yang YY*, Hou MC. GCKR Polymorphisms Increase the Risks of Low Bone Mineral Density in Young and Non-Obese Patients With MASLD and Hyperuricemia. *Kaohsiung J. Med. Sci.* 2025;41(6):- (IF:3.1)

34. ^{2,5}Li TH, Yeh HY, Lin SW, Huang YS, Zhuo ZW, Ma CC, Hsu TL, Wu WK, Tsai HC, Shen HC, Su CW, Yang YY*, Lin HC, Hou MC. Adenosine A2AR agonist blocks mesenteric lymphatic epithelium, adipose tissue and Treg cells links of metabolic dysfunction-associated steatotic liver disease mice. *Mol. Cell. Endocrinol.* 2025;610():-. (IF:3.6)
35. ^{2,5}Liao TL*, Chen DY, Hsieh SL, Yang YY, Chen YM, Tang KT, Chang CH, Yang SS. Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles. *Hepatology* 2025;82(3):722-738. (IF:16.8)
36. ^{2,5}Lim M, Espinoza M, Huang YH, Franses J, Zhu H, Hsiehchen D*. Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma. *JAMA Netw. Open* 2025;8(2):e2461735. (IF:9.7)
37. ^{2,5}Lin KL, Lin WY, Wang YP*, Luo JC, Hou MC, Lang HC, Lu CL*. Epidemiology and practice patterns of achalasia in Taiwan: A nationwide population-based cohort study. *J. Chin. Med. Assoc.* 2025;88(5):383-388. (IF:2.4)
38. ^{2,5}Liou JM*, Malfertheiner P, Hong TC, Cheng HC, Sugano K, Shah S, Sheu BS, Chen MJ, Chiang TH, Chen YC, Yamaoka Y, Wong SH, Chen CC, Lee YY, Quach DT, Wu DC, Hsu P, Wu CY, Wu JY, Luo JC, Chang WL, Lu H, Suzuki H, Jung HY, Mahachai V, Vilaichone RK, Megraud F, Lin JT, Yeoh KG, Leung WK, El-Omar EM*, Lee YC*, Wu MS*. Screening and eradication of *Helicobacter pylori* for gastric cancer prevention: Taipei Global Consensus II. *Gut* 2025;74(11):1767-1791. (IF:26.2)
39. ^{2,5}Lu CH, Chang CW, Chen SC, Kao WY, Ting WY, Lu CH, Chuang K, Ni CF, Hsieh YY, Wu MS, Su CW, Chang CC, Wu CH*. Machine Learning-Based Survival Analysis for Patients Receiving Lenvatinib for Unresectable Hepatocellular Carcinoma. *J. HEPATOCELL. CARCINOMA* 2025; 25:12:2625-2637. (IF:3.4)
40. ^{2,5}Lu CH, Kao WY, Wu CH, Ting WY, Lu CH, Chuang K, Ni CF, Hsieh YY, Wu MS, Su CW, Chen SC*. Predicting Survival Outcomes in Patients with Hepatocellular Carcinoma Receiving Lenvatinib by Using the Up7-ALBI Score. *Liver Cancer* 2025;14(6):704-717. (IF:9.1)
41. ^{2,5}Lu CY*, Tsai KF, Yen CJ, Hsieh CJ, Peng PJ, Huang SC, Chuang MR, Chu CJ*. Circulating tumor DNA methylation markers for the early diagnosis of hepatocellular carcinoma. *Clin. Exper. Med.* 2025;25(1):83. (IF:3.5)
42. ^{2,5}Manfredi GF, Fulgenzi CAM, Celsa C, Stefanini B, D'Alessio A, Pinter M, Scheiner B, Awosika N, Brunetti L, Lombardi P, Latchford C, Lee PC, Huang YH, Lin CY, Dalbeni A, Vogel A, Galle PR, Kudo M, Rimassa L, Chon HJ, Cabibbo G, Piscaglia F, Camma C, Pillai A, Pirisi M, Singal AG, Pinato DJ*. Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence. *JHEP Rep.* 2025;7(8): 101431. (IF:7.5)
43. ²Mon HC, Huang YH*. Reply to: "Immune checkpoint inhibitor therapy for functional cure

- of hepatitis 6 in cancer patients: A promising strategy?" and "Patients with HCC as an ideal study population to assess immune checkpoint inhibitors in hepatitis 6". *J. Hepatol.* 2025;82(3):e139-e140. (IF:33)
44. ^{2,5}Mon HC, Lee PC, Hung YP, Hung YW, Wu CJ, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH*. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. *J. Hepatol.* 2025;82(1):- (IF:33)
 45. ^{2,5}Shen HC, Tseng CH, Lin YH, Yeh HY, Tsai HC, Hong SY, Li TH, Su CW, Perng DW, Yang YY*, Hou MC. Protective effects of statins on pulmonary function in patients with persistent hyperlipidemia: a retrospective cohort study. *Ther. Adv. Respir. Dis.* 2025;19():-. (IF:3)
 46. ^{2,5}Shen SH, Tsai HJ, Li YH, Chen CC, Lin YC, Lee SW, Yang SS, Huang YH, Lee TY*. The Triglyceride-Glucose Index as a Biomarker for Insulin Resistance Following Hepatitis C Virus Eradication: A Prospective Cohort Study. *J. Clin. Med.* 2025;14(9):- (IF:2.9)
 47. ^{2,5}Stefanini B, Fulgenzi CAM, Scheiner B, Korolewicz J, Cheon J, Nishida N, Ang C, Marron TU, Wu YL, Saeed A, Wietharn B, Rimassa L, Pirozzi A, Cammarota A, Pressiani T, Pinter M, Balcar L, Huang YH, Mehan A, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schoenlein M, von Felden J, Schulze K, Wege H, Samson A, Galle PR, Kudo M, Manfredi GF, Celsa C, Awosika N, Cortellini A, Singal AG, Sharma R, Chon HJ, Tovoli F, Piscaglia F, Pinato DJ*, D'Alessio A*. ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab. *J. HEPATOCELL. CARCINOMA* 2025;12():671-683. (IF:3.4)
 48. ^{2,5}Tsai HC, Sun YS, Chen WS, Tsai WH, Huang DF, Yang YY, Liao HT*, Tsai CY*. Clinical and immunological differences between primary and autoimmune-associated neuromyelitis optica spectrum disorders: a retrospective study. *Lupus Sci. Med.* 2025;12(1):- (IF:4)
 49. ^{2,5}Tseng CH, Jou BY, Shen HC, Yeh HY, Hong SY, Lin YH, Tsai HC, Li TH, Su CW, Chou KT, Perng DW, Yang YY*, Hou MC. Increased risk of acute exacerbation in obstructive airway disease: the impact of metabolic dysfunction-associated steatotic liver disease and small airway dysfunction. *BMJ Open Respir. Res.* 2025;12(1):- (IF:3.4)
 50. ^{2,5}Tseng CH, Wong S, Yu J, Lee YY, Terauchi J, Lai HC, Luo JC, Kao CY, Yu SL, Liou JM, Wu DC, Hou MC, Wu MS, Wu JJ, Sung JJY*, El-Omar EM*, Wu CY*. Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium. *Gut* 2025;74(5):706-713. (IF:26.2)
 51. ^{2,5}Wang SJ, Huang CF, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Kuo HT, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Wang SC, Yu ML*. Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with

early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatitis C virus registry in Taiwan. *Kaohsiung J. Med. Sci.* 2025;41(2):- (IF:3.1)

52. ^{2,5}Wei CY*, Wen MS, Cheng CK, Sheen YJ, Yao TC, Lee SL, Wu JY, Tsai MF, Li LH, Chen CH, Fann CSJ, Yang HC, Huang YT, Chen HH, Liu YM, Yeh EC, Peng YC, Wang SJ, Chen SP, Tsai MT, Huo TL, Su CW, Tarng DC, Huang CC, Fuh JL, Lan KH, Liu YT, Lu CL, Lee YC, Huang YH, Li CP, Wang YF, Hsieh YC, Chen YM, Hsiao TH, Lin CH, Chen YJ, Chen IC, Mao CL, Chang SJ, Chang YL, Liao YJ, Lai CH, Lee WJ, Tung H, Yen TT, Yen HC, Chang JH, Huang CY, Chan L, Lin YW, Hsiao BY, Hu CJ, Lin YK, Lin YF, Chang TC, Wu DC, Kan JY, Hsu CY, Chen SC, Li CC, Huang CF, Sheu CC, Yang LJ, Chen CH, Chen KM, Chang SM, Liou MS, Wang SP, Lin KT, Chuang HP, Chen YJ, Sin J, Chen YT, Chang CC, Kuo CF, Lin JC, Kuo HC, Chan TM, Lee CW, Lai JH, Luo SF, Cheng HT, Lin LY, Chang LC, Tsai CT, Kao HL, Yu JJ, Jeng JS, Chiu MC, Hong TC, Yang SF, Lu HJ, Su SC, Chu PL, Li PF, Tsai CL, Tsai CK, Tang SE, Lin CM, Wu YF, Huang CY, Ling SZ, Chang CC, Lin TK, Hsiao SM, Chang CH, Chen CD, Ma GC, Chang TY, Hwang JJ, Lu CL, Kao KJ, Hung CF, Chen SS, Chen PY, Tsui K, Chen YT, Chen CH, Chien CC, Chiang HS, Chiu YL, Chen HC, Kwok PY. Clinical impact of pharmacogenetic risk variants in a large chinese cohort. *Nat. Commun.* 2025;16(1):- (IF:15.7)
53. ^{2,5}Weinstock JS*, Chaudhry SA, Ioannou M, Viskadourou M, Reventun P, Jakubek YA, Liggett LA, Laurie C, Broome JG, Khan A, Taylor KD, Guo XQ, Peyser PA, Boerwinkle E, Chami N, Kenny EE, Loos RJ, Psaty BM, Tracy RP, Brody JA, Yun JH, Cho MH, Vasan RS, Kardia SL, Smith JA, Raffield LM, Bidulescu A, O'Brien EC, de Andrade M, Rotter JJ, Rich SS, Tracy RP, Chen YDI, Gu CC, Hsiung CA, Kooperberg C, Haring B, Nassir R, Mathias R, Reiner A, Sankaran VG, Lowenstein CJ, Blackwell TW, Abecasis GR, Smith AV, Kang HM, Natarajan P, Jaiswal S, Bick A, Post WS, Scheet P, Auer P, Karantanos T, Battle A*, Arvanitis M*. Genetic determinants and genomic consequences of non-leukemogenic somatic point mutations. *Nat. Commun.* 2025;16(1):- (IF:15.7)
54. ²Wu KC, Lee IC*. Letter: Impact of HCV Eradication on Recurrence Pattern and Long-Term Outcomes in Patients With HCV-Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply. *Aliment. Pharmacol. Ther.* 2025;61(1):232-233. (IF:6.7)
55. ^{2,5}Wu M, Fulgenzi CAM, D'Alessio A, Cortellini A, Celsa C, Manfredi GF, Stefanini B, Wu YL, Huang YH, Saeed A, Pirozzi A, Pressiani T, Rimassa L, Schoenlein M, Schulze K, von Felden J, Mohamed Y, Kaseb AO, Vogel A, Roehlen N, Silletta M, Nishida N, Kudo M, Vivaldi C, Balcar L, Scheiner B, Pinter M, Singal AG, Glover J, Ulahannan S, Foerster F, Weinmann A, Galle PR, Parikh ND, Hsu WF, Parisi A, Chon HJ, Pinato DJ, Ang C*. Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab. *JHEP Rep.* 2025;7(2):- (IF:7.5)
56. ²Wu PS, Lee PC, Chang TE, Hsieh YC, Huang CW, Lin CH, Huang YL, Lin YT, Huo TI,

- Schnabl B, Lee KC*, Hou MC*. Fecal carriage of multidrug-resistant organisms increases the risk of hepatic encephalopathy in patients with cirrhosis: insights from gut microbiota and metabolite features. *Gut Pathogens* 2025;17(1):- (IF:4)
57. ^{2,5}Wu RK, Lee I-*. Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer-Reassurance With Vigilance. *Aliment. Pharmacol. Ther.* 2025;():-. (IF:6.7)
 58. ^{2,5}Wuputra K, Ku CC, Hsu WH, Hsieh TJ, Tsai YC, Chen CY, Tanaka Y, Lin YC, Kuo CH, Wu DC*, Yokoyama KK*. New insights into coordinated regulation of AHR promoter transcription; molecular mechanisms and therapeutic targets. *Int. J. Biol. Sci.* 2025;21(10):4504-4528. (IF:10)
 59. ^{2,5}Yeh HY, Lin SW, Shen HC*, Li TH, Tsai HC, Yang YY*, Lin HC, Hou MC. Complexity of metabolic dysfunction-associated steatotic liver disease: State of the art review. *J. Chin. Med. Assoc.* 2025;88(9):662-671. (IF:2.4)
 60. ^{2,5}Yeh HY, Pan MH, Huang CJ, Hong SY, Yang H*, Yang YY, Huang CC, Tsai HC, Li TH, Su CW, Hou MC. Triglyceride-glucose index and cancer risk: a prospective cohort study in Taiwan. *Diabetol. Metab. Syndr.* 2025;17(1):- (IF:3.9)
 61. ^{2,5}Yen FS, Hou MC, Wei JCC, Huang YH, Shih YH, Pan CW, Wang ST, Hwu CM*, Hsu CC*. Sodium-Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis. *Diabetes-Metab. Res. Rev.* 2025;41(5):- (IF:6)
 62. ^{2,5}Yen FS, Wei JCC, Wang C, Hou MC, Yu TS, Huang YH, Hwu CM*, Hsu CC*. Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients. *Diabetes Res. Clin. Pract.* 2025;223():-. (IF:7.4)
 63. ²Yu HY, Lee CY, Hu YC, Lin LG, Chao Y, Li CP*. Treatment rechallenge is safe and leads to better survival in pancreatic cancer patients with interstitial pneumonitis. *BMC Cancer* 2025;25(1):- (IF:3.4)
 64. ²Ma TH, Chen YJ*, Ho CT, Lee PC, Yang TC, Huang HC, Huang YH, Chen MH, Luo JC, Hou MC, Wu JC, Su CW. The Impact of Esophagogastric Varices on the Outcomes of Patients With Cholangiocarcinoma. *Clin. Transl. Gastroenterol.* 2025 Dec 1;16(12):e00930. doi: 10.14309 (IF:3.0)
 65. ^{2,5}Yang HC, Kwok PY, Li LH, Liu YM, Jong YJ, Lee KY, Wang DW, Tsai MF, Yang JH, Chen CH, Yeh EC, Wei CY, Fann CSJ, Huang YT, Chen CW, Lee YJ, Chu SK, Ho CH, Yang CS, Lee YL, Chen HH, Hou MC, Chiou JF, Yang SF, Wang CH, Huang CY, Chiu KM, Chen M, Chiang FT, Lee SL, Chen SS, Yao WJ, Chien CC, Lin SY, Chang FP, Ho HL, Yeh YC, Tseng WC, Lin MH, Chang HT, Tseng LM, Liang WY, Chen PCH, Hang JF, Lin SC, Chan YJ, Kuo YJ, Wang LC, Pan CC, Hsieh YC, Chen YM, Hsiao TH, Lin CH, Chen YJ, Chen IC, Mao CL, Chang SJ, Chang YL, Liao YJ, Lai CH, Lee WJ, Tung H, Yen TT, Yen HC, Shih CM, Chou TY, Liou TH, Chiang CY, Cherng YG, Chen CH, Chiu CH, Tseng SH, Lin EPY, Chen YJ, Chuang HP, Chen TC, Huang WT, Sin J, Liu IL, Chen YC, Chao KK, Wu YM, Yu PP, Chang

LP, Yen KY, Chang LC, Sheen YJ, Chen YT, Kan K, Tsai HL, Wang YK, Hou MF, Yang YH, Kuo CH, Wu WJ, Huang JF, Chong IW, Tsai JR, Lin CY, Yu MC, Lee TH, Tsai MH, Ou YC, Chen PY, Hu TH, Shyu YC, Cheng CK, Fang YJ, Hsieh SC, Chen CH, Chen CC, Li KJ, Lin CH, Chiu HY, Wu CC, Chen CY, Chu SJ, Liu FC, Yang FC, Chang HA, Chen WL, Yang SS, Sung YF, Wang TF, Lin SZ, Wu YW, Wu CS, Jiang JY, Ma GC, Chang TY, Hwang JJ, Kao KJ, Hung CF, Chiu TF, Chen PY, Tsui K, Wu MS, Pang ST, Chen SA, Chen WM, Chen CH, Sheu WHH, Wu JY. The Taiwan Precision Medicine Initiative provides a cohort for large-scale studies. *Nature*. 2025 Dec;648(8092):117-127. (IF:48.5)

66. ^{2,5}Shen HC, Huang PC, Pan ML, Yang CW, Ma CC, Tsai SY, Yeh HY, Lin YH, Yang YY*, Wang SJ. Effect of training content and environmental factors on resident retention rates in postgraduate year programs. *J Chin Med Assoc*. 2025 Dec 1;88(12):949-956. doi: 10.1097. (IF:2.4)
67. ²Huang HC*. Repurposing antihistamines beyond allergy control: Emerging therapeutic potentials in liver cirrhosis. *J Chin Med Assoc*. 2025 Dec 1;88(12):897-898. doi: 10.1097 (IF:2.4)

Endocrinology and Metabolism

1. ^{1,5}Chiang YL, Su GY, Tsai SC, Chen CN, Hwu CM, Wu TH. Wu TH*. Waist circumference is an important determinant of relative muscle strength in patients with type 2 diabetes mellitus. *J. Chin. Med. Assoc*. 2025;88(10):767-773. (IF:2.4)
2. ²Chen HH*, Chen CH, Hou MC, Fu YC, Li LH, Chou CY, Yeh EC, Tsai MF, Chen CH, Yang HC, Huang YT, Liu YM, Wei CY, Su JP, Lin WJ, Wang EHF, Chiang CL, Jiang JK, Lee IH, Liang KH, Chen WS, Tsai HC, Lin SY, Chang FP, Ho HL, Yeh YC, Tseng WC, Lin MH, Chang HT, Tseng LM, Liang WY, Chen PCH, Hsieh YC, Chen YM, Hsiao TH, Lin CH, Chen YJ, Chen IC, Mao CL, Chang SJ, Chang YL, Liao YJ, Lai CH, Lee WJ, Tung H, Yen TT, Yen HC, Chen MY, Lin YC, Kao YT, Kao BZ, Lee JE, Chung CL, Liu JC, Chan P, Lin CH, Chen CH, Wu IC, Lin LC, Wang JW, Shih SL, Hsieh SW, Hung CH, Li WM, Yang CJ, Yang CS, Weng RH, Chen YC, Chang CP, Wu TH, Lin YC, Sheen YJ, Wang SH, Chen SP, Raben T, Widen E, Hsu S, Hsieh FJ, Ho DR, Huang YH, Yang CH, Huang YS, Chen YF, Wu HM, Tsai PH, Huang KG, Chien CY, Ho YL, Wu MS, Kao JH, Liu YB, Juang JMJ, Lin MH, Lin YH, Lee JY, Lu HJ, Lu CH, Feng AC, Liu JS, Chiang CP, Chu NF, Lin JC, Yeh YW, Meng E, Huang CY, Li CC, Wang TF, Su KY, Wang JK, Chen MH, Chen HF, Ma GC, Chang TY, Chiang FT, Chang HJ, Kao KJ, Hung CF, Tsai CY, Chen PY, Tsui K, Chen YT, Kwok PY, Sheu WHH, Yang SF, Liou JM, Wang JY, Chiou JF, Wu JY, Fann CSJ*. Population-specific polygenic risk scores for people of Han Chinese ancestry. *Nature* 2025;648(8092):128-137. (IF:48.5)
3. ^{2,5}Chen KL, Chou RH*, Chang CC, Kuo CS, Wei JH, Lu YW, Teng H, Huang PH*, Lin SJ.

- Sepsis-associated liver dysfunction confounds the association between circulating PCSK9 concentration and mortality in septic patients: A single-center retrospective cohort study. *J. Crit. Care* 2025;90:155197. (IF:2.9)
4. ^{2,5}Chen MH, Lin LY, Hung TY, Lin TC, Li CY, Lin TH, Chen YH, Liou JT, Wang MT*. Comparative cardiovascular risk of sulfonylureas with low- and high-affinities for cardiac mitochondrial adenosine triphosphate-sensitive potassium channels versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A cohort study. *Diabetes Obes. Metab.* 2025;27(12):7502-7513. (IF:5.7)
 5. ^{2,5}Chen YG, Wei JCC, Yen FS, Sung CY, Huang YH, Yu TS, Tsai FJ, Hwu CM*, Hsu CC*. Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data. *BMC Med.* 2025;23(1): 587. (IF:8.3)
 6. ²Cheng WY, Yen FS, Hung YM, Wei JCC, Lin HJ, Huang YH, Hsu CC, Hwu CM*. SGLT2 inhibitors for primary prevention of macrovascular and major microvascular complications in type 2 diabetes: an island-wide cohort study. *J. R. Soc. Med.* 2025;118(11):347-357. (IF:10.3)
 7. ^{2,5}Hsu PWC, Chen YR, Sheu WHH*. MetS-Z: A gender- and age-specific scoring system for predicting type 2 diabetes. *J. Diabetes Investig.* 2025;16(5):907-916. (IF:3)
 8. ^{2,5}Hsu PWC, Yeh CH, Lo CJ, Tsai TH, Chan YH, Chou YJ, Yang N, Cheng ML, Sheu WHH, Lai CC*, Sytwu HK*, Tsai TF*. Trans-omics analyses identify the biochemical network of LPCAT1 associated with coronary artery disease. *Biomark. Res.* 2025;13(1):107. (IF:11.5)
 9. ^{2,5}Hung TY, Lin TC, Liou YJ, Lin TH, Hsu YJ, Lin LY*, Wang MT*. Use of dipeptidyl peptidase-4 inhibitors is associated with lower risk of severe renal outcomes in pre-dialysis patients with Type 2 diabetes. *J. Intern. Med.* 2025;298(3):214-227. (IF:9.2)
 10. ¹Ko FS, Wu TH, Su GY, Lin YH, Juan CC, Hwu CM*. Blood Cell Count-Based Inflammatory Markers Exhibit Superior Association with Diabetic Peripheral Neuropathy Compared to Protein-Based Markers. *J. Inflamm. Res.* 2025;18():10609-10617. (IF:4.1)
 11. ¹Lee CC, Ko FS, Yen FS*, Hwu CM*. LX9211, a rising star for relieving of diabetic peripheral neuropathic pain. *J. Diabetes Investig.* 2025;16(2):176-179. (IF:3)
 12. ²Lee PS, Chen JY, Kuo PC, Lee CC, Chen PL, Chen HS, Huang CJ*. Influence of Preoperative Thyroid Status on Clinical Outcomes in Graves' Disease Undergoing Thyroidectomy. *World J.Surg.* 2025;49(9):2464-2473. (IF:2.5)
 13. ²Lee PS, Chen JY, Lee CC, Pan LH, Hang JF, Kuo PC, Yao SF, Hwu CM*, Kuo CS*. Validation of preoperative BRAF V600E testing by ThyroSCAN PanelChip in thyroid nodules. *Endocr. Connect.* 2025;14(5):- . (IF:2.8)
 14. ^{2,5}Liao TY, Lin YC, Huang CJ, Hwu CM, Lin LY*. Clinical efficacy and safety of fluconazole treatment in patients with Cushing's syndrome. *Ther. Adv. Endocrinol. Metab.* 2025;16:20420188251372275. (IF:4.6)

15. ²Lin DC, Hou JY, Tseng CK, Tsai PS*. The changes in imaging following proton beam therapy for pediatric hepatoblastoma. *Eur. J. Pediatr.* 2025;184(10):626. (IF:2.6)
16. ²Lin DC, Tsai PS, Lin TL, Huang WH, Liu YP, Wu TH, Shih CT*. Predicting complications and morbidities in PAD patients through lower extremity compositions with dual-energy CT and material decomposition: a 2-year follow-up observational study. *BMC Cardiovasc. Disord.* 2025;25(1):268. (IF:2.3)
17. ²Lin LY*, Chang TT, Leu HB, Huang CC, Wu TC, Chou RH, Huang PH, Yin WH, Tseng WK, Wu YW, Lin TH, Yeh H, Chang KC, Wang JH, Wu CC, Chen JW*. Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease. *Clin. Res. Cardiol.* 2025;114(8):952-968. (IF:3.7)
18. ²Lin LY, Lin YH, Chueh SJ, Yeh CH, Wu CH, Cheng HM, Hwang SJ, Liu FH, Yang J, Wu VC*. Universal Screening for Primary Aldosteronism in Hypertensive Patients: A 2025 Taipei Positional Paper. *J. Clin. Hypertens.* 2025;27(9):e70102. (IF:2.5)
19. ^{2,5}Lin TH, Hung TY, Lin LY, Lin TC, Liou YJ, Hsu YJ, Wang MT*. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease Requiring Dialysis. *Pharmacoepidemiol. Drug Saf.* 2025;34(4):e70138. (IF:2.4)
20. ^{2,5}Liu SY, Chen LK, Li PH, Wu GL, Wu TH, Yu YB*, Lin HF*, Juan CC*. Glucosamine induces hepatic FGF21 expression by activating the Akt/mTOR/p70S6K axis and driving PGC-1 α activity. *Sci Rep* 2025;15(1):13096. (IF:3.9)
21. ^{2,5}Pan LH, Yeh CC, Yang SJ, Yang CC, Hwu CM, Chen HS, Wang FF, Huang CJ*. A Prospective Study to Determine Trimester-Specific Thyroid Function Reference Intervals. *J. Endocrinol. Invest.* 2025;48(10):2351-2360. (IF:3.5)
22. ^{2,5}Pan LH, Yeh CC, Yang SJ, Yang CC, Hwu CM, Chen HS, Wang FF, Huang CJ*. Iodine nutritional status in different trimesters of pregnancy and its association with dietary habits: a prospective observational study in Taiwan. *BMC Pregnancy Childbirth* 2025;25(1):323. (IF:2.7)
23. ^{1,5}Sheu WH*, Lee C-Y, Wang Y-, Liao C-, Hsiao T-, Suzuki K, Hatzikotoulas K, Morris AP, Chen YI, Rotter JI*. Glycaemic responses to metformin monotherapy by SNP clusters in patients with type 2 diabetes. *Diabetes Obes. Metab.* 2025;27(11):6323-6332. (IF:5.7)
24. ^{2,5}Smit RAJ, Wade KH, Hui Q, Arias JD, Yin XY, Christiansen MR, Yengo L, Preuss MH, Nakabuye M, Rocheleau G, Graham SE, Buchanan VL, Chittoor G, Graff M, Guindo-Martinez M, Lu YC, Marouli E, Sakaue S, Spracklen CN, Vedantam S, Wilson EP, Chen SH, Ferreira T, Ji YJ, Karaderi T, Lull K, Machado M, Malden DE, Medina-Gomez C, Moore A, Rueger S, Akiyama M, Allison MA, Alvarez M, Andersen MK, Appadurai V, Arbeeve L, Bartell E, Bhaskar S, Bielak LF, Bis JC, Bollepalli S, Bork-Jensen J, Bradfield JP, Bradford Y, Brandl C, Braund PS, Brody JA, Broeckel U, Burgdorf KS, Cade BE, Cai QY, Camarda S, Campbell A, Canadas-Garre M, Chai JF, Chesi A, Choi SH, Christofidou P, Couture C,

- Cuellar-Partida G, Danning R, Degenhardt F, Delgado GE, Delitala A, Demirkan A, Deng X, Dietl A, Dimitriou M, Dimitrov L, Dorajoo R, Eliassen AU, Engmann JE, Erdos MR, Fairhurst-Hunter Z, Farmaki AE, Faul JD, Fernandez-Lopez JC, Forer L, Frank M, Freitag-Wolf S, Fritsche LG, Fuchsberger C, Galesloot TE, Gao Y, Geller F, Giannakopoulou O, Giulianini F, Gjesing AP, Goel A, Gordon SD, Gorski M, Grove J, Guo XQ, Gustafsson S, Haessler J, Hansen TF, Havulinna AS, Haworth SJ, Heard-Costa N, Hemerich D, Highland HM, Hindy G, Ho YL, Hofer E, Holliday E, Horn K, Hornsby WE, Hottenga JJ, Huang HY, Huang J, Huerta-Chagoya A, Huo SF, Hwang MY, Hwu CM, Iha H, Ikeda DD, Isono M, Jackson AU, Jansen IE, Jiang YX, Johansson I, Jonsson A, Jorgensen T, Kalafati IP, Kanai M, Kanoni S, Karhus LL, Kasturiratne A, Katsuya T, Kawaguchi T, Kember RL, Kentistou KA, Kim D, Kim HN, Kim YJ, Kleber ME, Knol MJ, Kurbasic A, Lauzon M, Le P, Lea R, Lee JY, Lee WJ, Leonard HL, Li HT, Li SCA, Li XH, Li XY, Liang JJ, Lin HH, Lin K, Liu J, Liu XP, Lo KS, Long JR, Lores-Motta L, Luan JA, Lyssenko V, Lyytikainen LP, Mahajan A, Malik MZ, Mamakou V, Mangino M, Manichaikul A, Marten J, Mattheisen M, McDaid AF, Mei QS, Meiselbach H, Melendez TL, Milaneschi Y, Miller JE, Millwood IY, Mishra PP, Mitchell RE, Mollehave LT, Mononen N, Mucha S, Munz M, Mykkaenen J, Nakatochi M, Nardone GG, Nelson CP, Nethander M, Nho CW, Nielsen AA, Nolte IM, Nongmaithem SS, Noordam R, Ntalla I, Nutile T, Pandit A, Pauper M, Peters ERB, Peters LV, Piluso F, Polasek O, Poveda A, Pyarajan S, Raffield LM, Rakugi H, Ramirez J, Rasheed A, Raven D, Rayner NW, Riveros C, Rohde R, Ruggiero D, Ruotsalainen SE, Ryan KA, Sabater-Lleal M, Santin A, Saxena R, Scholz M, Shen BT, Shi JCZ, Shin JH, Sidore C, Sidorenko J, Sim X, Slieker RC, Smith AV, Smith JA, Smyth LJ, Southam L, Steinthorsdottir V, Sun L, Takeuchi F, Taylor KD, Tayo BO, Tcheandjie C, Terzikhan N, Tesolin P, Teumer A, Theusch E, Thompson DJ, Thorleifsson G, Timmers PRHJ, Trompet S, Turman C, Vaccargiu S, van der Laan SW, van der Most PJ, van Klinken JB, van Setten J, Verma SS, Verweij N, Vetruri Y, Wang CA, Wang CL, Wang JS, Wang LH, Wang YX, Wang Z, Warren HR, Wei WB, Wen WQ, Wheeler WA, Wickremasinghe AR, Wielscher M, Winsvold BS, Wong A, Wuttke M, Xia R, Yamamoto K, Yang JY, Yao J, Young H, Yousri NA, Yu L, Zeng LY, Zhang WH, Zhang XY, Zhao JH, Zhao W, Zhou W, Zimmermann ME, Zoledziewska M, 't Hart LM, Adair LS, Adams HHH, Aguilar-Salinas CA, Al-Mulla F, Arnett DK, Asselbergs FW, Asvold BO, Attia J, Banas B, Bandinelli S, Beilin LJ, Bennett DA, Bergler T, Bharadwaj D, Biino G, Boerwinkle E, Boeger CA, Borja JB, Bouchard C, Bowden DW, Brandslund I, Ben Brumpton, Buring JE, Caulfield MJ, Chambers JC, Chandak GR, Chanock SJ, Chaturvedi N, Chen YDI, Chen ZM, Cheng CY, Cho YS, Christensen K, Christophersen IE, Ciullo M, Cole JW, Collins FS, Concas MP, Cooper RS, Cruz M, Cucca F, Cutler MJ, Damrauer SM, Dantoft TM, de Borst GJ, de Geus. Polygenic prediction of body mass index and obesity through the life course and across ancestries. *Nat. Med.* 2025;31(9):3151-3168. (IF:50)
25. ^{2,5}Su YW, Sheu WHH, Hwu CM, Chen YC, Chen JF, Peng YS, Huang CN, Hung YJ, Chen HS*. Application of machine learning algorithms to identify risk factors for depression in type

- 2 diabetes mellitus patients: A Taiwan diabetes registry study. *J. Chin. Med. Assoc.* 2025;88(7):513-519. (IF:2.4)
26. ²Sung JH, Ko FS, Wu TH, Tsai SC, Hwu CM*, Su GY*. Ratio of fat-free mass to fat mass is associated with physical performance in patients with type 2 diabetes mellitus. *Front. Endocrinol.* 2025;16:1562870. (IF:4.6)
27. ^{1,5}Tiwaskar M, Hwu CM*, Lim M, Bhandary A, Chang I. Treatment Preferences for Novel Type 2 Diabetes Oral Medications: Insights from the Asian Diabetes Patient Preference Study. *Diabetes Ther.* 2025;16(9):1841-1859. (IF:2.6)
28. ^{2,5}Wu IW, Liao YC, Tsai TH, Lin CH, Shen ZQ, Chan YH, Tu CW, Chou YJ, Lo CJ, Yeh CH, Chen CY, Pan HC, Hsu HJ, Lee CC, Cheng ML, Sheu WHH, Lai CC*, Sytwu HK*, Tsai TF*. Machine-learning assisted discovery unveils novel interplay between gut microbiota and host metabolic disturbance in diabetic kidney disease. *Gut Microbes* 2025;17(1):2473506. (IF:11)
29. ^{2,5}Wu YW, Chen JW, Lin LY, Huang JH, Chang CC, Chang TT*. FABP4 inhibition protects renal tubular cells and ameliorates renal inflammation in diabetic kidney disease. *Biochem. Pharmacol.* 2025;236:116899. (IF:5.6)
30. ²Yang JH, Matthew-Duncan L, Laws H, Isles S, Shu YF, Lee Y, Lin LX, Kang SY, Hsu HW, Hwu CM, Chen HC*, Su GY*. The metabolic chronic disease prevention program in Saint Kitts and Nevis: a dietary recall study. *Front. Nutr.* 2025;12:1617389. (IF:5.1)
31. ²Yang JH, Wang WH, Chen HS*. Evaluating pituitary tumor management: aligning with pituitary tumor centers of excellence criteria. *Pituitary* 2025;28(5):91. (IF:3.4)
32. ²Yeh HY, Pan MH, Huang CJ, Hong SY, Yang H*, Yang YY, Huang CC, Tsai HC, Li TH, Su CW, Hou MC. Triglyceride-glucose index and cancer risk: a prospective cohort study in Taiwan. *Diabetol. Metab. Syndr.* 2025;17(1):283. (IF:3.9)
33. ^{2,5}Yeh HY, Shih ML, Chang JW, Lin LY, Kao ZK, Hsieh AR, Tsai PH, Wang JT*, Chen YC*. Voluntary vitamin D testing: a decade-long study of utilisation patterns and impact on deficiency outcomes in Taiwan. *Public Health Nutr.* 2025;28(1):e171. (IF:3)
34. ^{2,5}Yen FS*, Wang SW, Hung YM, Hsu CC, Hwu CM*, Wei JC-C*. Impact of glucagon-like peptide-1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes. *Diabetes Obes. Metab.* 2025;27(11):6403-6415. (IF:5.7)
35. ^{2,5}Yen FS, Hou MC, Wei JCC, Huang YH, Shih YH, Pan CW, Wang ST, Hwu CM*, Hsu CC*. Sodium-Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis. *Diabetes-Metab. Res. Rev.* 2025;41(5):e70070. (IF:6)
36. ^{2,5}Yen FS, Hsu CC, Yeh YK, Cheng WY, Liao PL, Hwu CM*, Wei JCC*. The impact of sodium-glucose cotransporter-2 inhibitors on dialysis risk and mortality in kidney transplant patients with diabetes. *Am. J. Transplant.* 2025;25(9):1954-1964. (IF:8.2)
37. ^{2,5}Yen FS, Huang JY, Dong C, Hwu CM, Hsu CC*, Wei JCC*. Impact of SGLT2 inhibitors on

- kidney health and survival in patients with polycystic kidney disease and type 2 diabetes. *Diabetes Res. Clin. Pract.* 2025;226:112357. (IF:7.4)
38. ^{2,5}Yen FS, Hung YM, Huang JY, Hsu CC, Cheng WY, Hwu CM*, Wei JCC*. Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetes. *J. Intern. Med.* 2025;297(5):532-542. (IF:9.2)
 39. ^{2,5}Yen FS, Wang SI, Hwu CM, Haung CW, Chang RN, Hsu CC*, Wei JCC*. Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. *J. Autoimmun.* 2025;157:103493. (IF:7)
 40. ^{2,5}Yen FS, Wei JCC, Cheng WY, Huang CT, Wu YL, Teh SH, Hwu CM, Hsu CC*. Low birth weight and chronic kidney disease with progression to kidney failure in children. *Nephrol. Dial. Transplant.* 2025;40(8):1550-1558. (IF:5.6)
 41. ^{2,5}Yen FS, Wei JCC, Huang YH, Hsu TJ, Wang ST, Hwu CM*, Hsu CC*. SGLT-2 Inhibitors and the Risk of Chronic Obstructive Pulmonary Disease Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease Patients. *Ann. Am. Thoracic Society* 2025;22(6):846-854. (IF:5.4)
 42. ^{2,5}Yen FS, Wei JCC, Huang YH, Li PY, Tsai FJ, Hsu CC*, Hwu CM*. Comparative outcomes of adding SGLT2 inhibitors versus incretin-based therapies to insulin in type 2 diabetes. *Diabetes Res. Clin. Pract.* 2025;226:112328. (IF:7.4)
 43. ^{2,5}Yen FS, Wei JCC, Hung YM, Li PY, Hsu CC*, Hwu CM*. SGLT2 Inhibitors and Prevention of Cardiovascular Events in Diabetes Patients with and Without Hypertension: A Nationwide Cohort Study. *J. Gen. Intern. Med.* 2025. (IF:4.2)
 44. ^{2,5}Yen FS, Wei JCC, Hung YM, Liu JS, Hwu CM*, Hsu CC*. Income and wealth inequality is associated with young-onset type 2 diabetes. *World J. Diabetes* 2025;16(9):108480. (IF:4.6)
 45. ^{2,5}Yen FS, Wei JCC, Ko FS, Huang YH, Yip HT, Tsai FJ, Hwu CM*. Association of DPP-4 inhibitors with respiratory and cardiovascular complications in patients with COPD: a nationwide cohort study. *ERJ Open Res.* 2025;11(3):00919-2024. (IF:4)
 46. ^{2,5}Yen FS, Wei JCC, Lin SY, Hsu JF, Yeh YK, Huang YH, Hsu TJ, Cho DY, Hwu CM*, Hsu CC*. The Impact of Pay-for-Performance Care on the Mortality and Cardiovascular Outcomes in Older Adults with Newly Diagnosed Type 2 Diabetes: A Nationwide Population-Based Cohort Study. *J. Am. Med. Dir. Assoc.* 2025;26(2):105382. (IF:3.8)
 47. ^{2,5}Yen FS, Wei JCC, Lu WY, Yen YH, Wu YL, Lo YR, Hwu CM*, Hsu CC*. Income-related inequities in the progression from gestational to type 2 diabetes: Findings from Taiwan's maternal and child health database. *Diabetes Obes. Metab.* 2025. (IF:5.7)
 48. ^{2,5}Yen FS, Wei JCC, Sung CY, Li PY, Tsai FJ, Hsu CC*, Hwu CM*. Impact of Adding GLP-1 Receptor Agonists to Insulin Therapy on Cardiovascular and Microvascular Outcomes in Type 2 Diabetes: A Nationwide Cohort Study from Taiwan. *Pharmaceuticals* 2025;18(9).

(IF:4.8)

49. ^{2,5}Yen FS, Wei JCC, Wang C, Hou MC, Yu TS, Huang YH, Hwu CM*, Hsu CC*. Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients. *Diabetes Res. Clin. Pract.* 2025;223:112174. (IF:7.4)
50. ^{2,5}Yen FS, Wei JCC, Wu YL, Lo YR, Chen CM, Hwu CM, Hsu CC*. Impact of family income on the development of gestational diabetes mellitus and the associated birth outcomes: A nationwide study. *J. Diabetes Investig.* 2025;16(1):51-59. (IF:3)
51. ^{2,5}Yen FS, Yen YH, Hung YM, Wei JCC, Tsai FJ, Hung YT, Lin HJ, Hwu CM*, Hsu CC*. Diabetic Microvascular Disease and Risk of Peripheral Artery Disease, Foot Ulcer, Leg Infection, and Amputation. *Thromb. Haemost.* 2025. (IF:4.3)
52. ^{2,5}Yen HY, Lin YH, Wang YF, Fuh JL, Wang SJ, Chen HS, Chiang SC, Li SR, Lin MH, Chen TJ, Hwang SJ, Chang HT*. The association between metabolic syndrome components and cognitive function in community-dwelling middle-aged and older adults: the first wave result of a cohort study. *J. Health Popul. Nutr.* 2025;44(1):94. (IF:2.8)
53. ^{2,5}Yen YH, Wei JCC, Yen FS, Kao YS, Lin HJ, Cho DY, Hwu CM*, Hsu CC*. Microvascular Complications and Cancer Risk in Type 2 Diabetes: A Population-Based Study. *Cancers* 2025;17(11):1760. (IF:4.4)
54. ^{2,5}Yueh MP, Kao SK, Chen JW, Huang JC, Chen HS, Wu TE*. Psoriasis and risk of diabetic retinopathy in patients with type 2 diabetes mellitus. *Diabetes Res. Clin. Pract.* 2025;229:112912. (IF:7.4)
55. ^{2,5}Zhang XR*, Brody JA, Graff M, Highland HM, Chami N, Xu HFF, Wang Z, Ferrier KR, Chittoor G, Josyula NS, Meyer M, Gupta S, Li XH, Li ZL, Allison MA, Becker DM, Bielak LF, Bis JC, Boorgula MP, Bowden DW, Broome JG, Buth EJ, Carlson CS, Chang KM, Chavan S, Chiu YF, Chuang LM, Conomos MP, Demeo DL, Du MM, Duggirala R, Eng C, Fohner AE, Freedman BI, Garrett ME, Guo XQ, Haiman C, Heavner BD, Hidalgo B, Hixson JE, Ho YL, Hobbs BD, Hu DL, Hui Q, Hwu CM, Jackson RD, Jain D, Kalyani RR, Kardina SLR, Kelly TN, Lange EM, Lenoir M, Li CW, Le Marchand L, McDonald MLN, Mchugh CP, Morrison AC, Naseri T, O'Connell J, O'Donnell CJ, Palmer ND, Pankow JS, Peters U, Preuss MH, Rao DC, Regan EA, Reupena SM, Roden DM, Rodriguez-Santana J, Sitlani CM, Smith JA, Tiwari HK, Vasan RS, Wang ZY, Weeks DE, Wessel J, Wiggins KL, Wilkens LR, Wilson PWF, Yanek LR, Yoneda ZT, Zhao W, Zollner S, Arnett DK, Ashley-Koch AE, Barnes KC, Blangero J, Boerwinkle E, Burchard EG, Carson AP, Chasman DI, Chen YDI, Curran JE, Fornage M, Gordeuk VR, He J, Heckbert SR, Hou LF, Irvin MR, Kooperberg C, Minster RL, Mitchell BD, Nouraie M, Psaty BM, Raffield LM, Reiner AP, Rich SS, Rotter JI, Shoemaker MB, Smith NL, Taylor KD, Telen MJ, Weiss ST, Zhang YZ, Heard-Costa N, Sun YV, Lin XH, Cupples LA, Lange LA, Liu CT, Loos RJJ, North KE, Justice AE*. Whole genome sequencing analysis of body mass index identifies novel African ancestry-specific risk allele. *Nat.*

Commun. 2025;16(1):3470. (IF:15.7)

Infectious Diseases

1. ²Lu CT, Fang TP, Hung MS*, Lin YT*. Clinical outcomes in ventilator-associated pneumonia patients with and without chronic obstructive pulmonary disease. *J. Chin. Med. Assoc.* 2025;88(1):65-70. (IF:2.4)
2. ^{2,5}Chang YY*, Kuo SC, Ku SWW*. Detection of cytomegalovirus in severely ill patients with intractable COVID-19; a retrospective study. *BMC Public Health* 2025;25(1):- (IF:3.6)
3. ^{2,5}Chen APL, Cheng CY, Lee CY, Liu WD, Ho MW, Chen WY, Chen TC, Liou BH, Chuang HC, Tsai MS, Cheng MY, Tang HJ, Tsai HC, Lee MH, Chen KH, Lee CH, Liu CW, Lee YC, Yang CH, Yang CJ*. Disproportionate presentation of Mpox among people with HIV: A multicenter retrospective cohort study in Taiwan. *J. Microbiol. Immunol. Infect.* 2025;58(6):663-669. (IF:3.7)
4. ²Chuang C, Kao TC, Juan CH, Chou SH, Ho YC, Liu SY, Huang YR, Ho HL, Lin YT*. Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy. *Infect. Dis. Ther.* 2025;14(5):1027-1042. (IF:5.3)
5. ^{1,5}Ho YC, Chang MC, Lin WY, Wu CY, Liu SY, Chuang C, Juan CH, Liu CJ, Lin YT*. Prognostic factors of disease progression in patients with mild-to-moderate COVID-19 on early remdesivir treatment in Taiwan. *J. Infect. Public Health* 2025;18(5):- (IF:4)
6. ^{2,4}Hsu CH, Hsuan YT, Chan YJ, Chen HP*. Clinical presentation of cytomegalovirus meningoencephalitis: a retrospective study of 12 adult patients with a variety of immunocompromised conditions. *BMC Infect. Dis.* 2025;25(1):- (IF:3)
7. ^{2,5}Hsu JY, Wu UI*, Wang JT, Sheng WH, Chen YC, Chang SC. Managing *Helicobacter pylori* as an Infectious Disease: Implementation of Antimicrobial Stewardship. *Helicobacter* 2025;30(1):- (IF:4.3)
8. ^{1,4}Hsuan YT, Hsu CH, Chen CY, Chan YJ, Chen HP*. Clinical characteristics and prognostic factors in patients with stool cytomegalovirus positivity. *J. Chin. Med. Assoc.* 2025;88(11):836-843. (IF:2.4)
9. ^{2,5}Juan CH, Chou SH, Chuang C, Lin SN, Wu XN, Liu SY, Ho YC, Lin YT*. Carbapenems versus non-carbapenems as definitive treatment for hypervirulent *Klebsiella pneumoniae* bacteremia in Taiwan. *Antimicrob. Agents Chemother.* 2025;69(12):- (IF:4.5)
10. ²Ku RH, Lu HF, Li LH, Yeh TY, Lin YT, Yang TC*. Roles of the *rpoEc*-*chrR*-*chrA* operon in superoxide tolerance and β -lactam susceptibility of *Stenotrophomonas maltophilia*. *Front. Cell. Infect. Microbiol.* 2025;15():- (IF:4.8)
11. ⁵Lee PI*, Huang YC, Liu CC, Chen SU, Hsueh PR, Ku SC, Chen PY, Chen CJ, Lin YT, Lu CY, Chiu NC, Chi H, Chen YC, Chang FY, Yen MY, Lu CT, Yang KY, Chiu CH, Hwang KP,

- Lee WS, Yen TY, Hsu JF, Lin YC, Hu YL, Lin TY. Recommendation for the use of respiratory syncytial virus vaccines. *J. Microbiol. Immunol. Infect.* 2025;58(1):1-6. (IF:3.7)
12. ⁵Lin KY, Lin IF, Wu PF, Tsai WC, Su LY, Chang CN, Huang WH, Wang CH, Hung MC, Huang CH, Chiu NC, Cheng MF, Hsieh SM, Wang NC, Lee PI, Lu CY, Wang HW, Wong SS, Lin PC, Tsai MH, Yang SC, Hsu YL, Lee SSJ*, Chen YC*, Wang FD, Taiwan Urological Assoc. Recommendations and guidance for human papillomavirus (HPV) vaccination for adults in Taiwan. *J. Microbiol. Immunol. Infect.* 2025;58(4):383-396. (IF:3.7)
 13. ^{2,4}Lin TA, Lin YT, Liu CJ*. Cryptococcal antigen cross-reactivity is associated with fatal trichosporonosis in patients with hematologic diseases. *Eur. J. Clin. Microbiol. Infect. Dis.* 2025;44(12):2955-2964. (IF:3)
 14. ²Lin YT*, Lin SN, Chuang C, Liu SY, Ho YC, Juan CH, Ho HL, Chou SH. Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant *Klebsiella pneumoniae* bacteremia. *J. Infect. Public Health* 2025;18(9):- (IF:4)
 15. ¹Liu SY, Chou SH, Chuang C, Juan CH, Ho YC, Ho HL, Chen L, Lin YT*. Clinical and Microbiological characteristics of patients with ceftazidime/avibactam-resistant *Klebsiella pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae* strains. *Ann. Clin. Microbiol. Antimicrob.* 2025;24(1):- (IF:3.6)
 16. ¹Liu SY, Chuang C, Juan CH, Ho YC, Chou SH, Huang YR, Chin W, Ho HL, Lin YT*. Comparison of Effectiveness between Ceftazidime/Avibactam and Other Active Therapies for Oxacillinase-48-Producing Carbapenem-Resistant *Klebsiella pneumoniae* Bacteremia in Taiwan. *Infect. Dis. Ther.* 2025;14(9):2143-2156. (IF:5.3)
 17. Vu TT*, Rupasinghe D, Khol V, Chaiwarith R, Tanuma J, Kumarasamy N, Khusuwan S, Somia IA, Pujari S, Lee MP, Borse RT, Kiertiburanakul S, Yuniastuti E, Azwa I, Choi JY, Chen HP, Ditangco R, Avihingsanon A, Gani Y, Ross J, Jiamsakul A, IeDEA Asia-Pacific. Temporal trends from HIV diagnosis to ART initiation among adults living with HIV in the Asia-Pacific (2013-2023). *Aids Res. Ther.* 2025;22(1):- (IF:2.5)
 18. ^{1,4}Wu PS, Lee PC, Chang TE, Hsieh YC, Huang CW, Lin CH, Huang YL, Lin YT, Huo TI, Schnabl B, Lee KC*, Hou MC*. Fecal carriage of multidrug-resistant organisms increases the risk of hepatic encephalopathy in patients with cirrhosis: insights from gut microbiota and metabolite features. *Gut Pathogens* 2025;17(1):- (IF:4)
 19. ²Yang TC, Wu SC, Yeh TY, Lu HF, Lin YT, Li LH*. NagPIBAF upregulation and ompO downregulation compromise oxidative stress tolerance of *Stenotrophomonas maltophilia*. *BMC Microbiol.* 2025;25(1):- (IF:4.2)
 20. ⁵Yang TY, Huang CT, Liu PY, Lin YT, Huang YS, Chang PH, Tseng CH, Chang YT, Lu PL*, Chen YC. Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study. *J. Infect. Public Health*

2025;18(6):- (IF:4)

21. ²Yeh TY, Lu HF, Li LH, Lin YT, Yang TC*. Contribution of fepAsm, fciABC, sbaA, sbaBCDEF, and feoB to ferri-stenobactin acquisition in *Stenotrophomonas maltophilia* KJ. BMC Microbiol. 2025;25(1):- (IF:4.2)

Nephrology

1. ^{2,5}Chen CM, Lin CC, Wu CC, Tsai JR*. Mixture mean residual life model for competing risks data with mismeasured covariates. J. Appl. Stat. 2025;52(7):1361-1380. (IF:1.1)
2. ²Chen CY, Huang SS, Ou SM, Ho Y, Chen TH, Lee KH, Chu YC, Lin YP, Tseng WC* Tarng DC*. Excessive Initial Renal Function Decline Following Sodium-Glucose Cotransporter-2 Inhibitor Treatment Predicts Major Adverse Cardiorenal Outcomes. Mayo Clin Proc. 2025 Feb; 100 (2) :204-219. (IF:6.7)
3. ^{2,5}Wu CL*, Hsu JW, Chan YC, Yu JY, Tsai YL, Tarng DC*. Depleting Yes-Associated Protein in Gli1-Expressing Cells Attenuates Peritoneal Dialysis-Induced Peritoneal Fibrosis. J Cell Mol Med. 2025 Mar;29(6):e70516. (IF:4.2)
4. ²Chen LC, Kao ZK, Yang CY*, Tarng DC. Urine Albumin-creatinine Ratio Accurately Reflects Daily Albuminuria in Nonobese Patients but Requires Body Weight Correction in Obese. J Ren Nutr. 2025 Sep;35(5):607-615. (IF:3.2)
5. ²Hsu TJ, Tseng CT, Kuo L, Yang CY*, Lin YP, Yu WC, Tarng DC. AHL amyloidosis mimicking transthyretin amyloidosis on cardiac Tc-99 m pyrophosphate scan: A diagnostic challenge. J Nucl Cardiol. 2025 May;47:102147. (IF:2.7)
6. ²Chen TH, Ou SM, Lin KH, Ho Y, Tseng WC, Chu YC*, Tarng DC*. Effect of spironolactone on cardiovascular and renal outcomes in patients with chronic kidney disease. Clin Kidney J. 2025 Aug 6;18(9):sfaf247. (IF:4.6)
7. ²Chen CY, Huang SS, Tarng DC*, Tseng WC*. In Reply: eGFR Decline at Initiation of Sodium-Glucose Cotransporter 2 Inhibitors. Mayo Clin Proc. 2025 Sep;100(9):1671-1672. (IF:6.7)
8. ²Chen TH, Shiu YT, Lee T, Yang CY, Tarng DC*. Hemodialysis vascular access flow surveillance: Current evidence and future directions. J Chin Med Assoc. 2025 Nov 1;88(11):815-824. (IF:2.4)
9. ^{2,5}Huang JW, Chen CH, Tsai MT, Hu PA, Guo BC, Chen WH, Chen HW, Lee TS*, Tarng DC*. Genetic deletion of TRPM8 channels restores microvascular function and mitigates chronic kidney disease progression. Free Radic Biol Med. 2025 Dec 16;241:659-670. (IF:8.2)
10. ^{2,5}Hou YC, Wu CL, Tseng WC, Wang J, Lu KC, Zheng CM, Liu JS, Kuo KL, Tarng DC*. Comparative effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on prognosis in non-dialysis chronic kidney disease: a propensity-matched cohort study. Ren Fail. 2025 Dec;47(1):2592442. (IF:3)
11. Chen FY, Tan AC, Chen CM, Yang CY, Lee KH, Ou SM, Tsai MT, Li SY, Lin TJ, Kao ZK, Tseng CT, Fu YH, Lin CC* The association of vascular access flow with sacubitril/valsartan and left ventricular ejection fraction in hemodialysis patients with heart failure with reduced ejection fraction. Clin Kidney J 2025 Mar 25;18(4):sfaf078. (IF:4.6)

12. ²Lin YT, Tsai MT, Chen TW, Lin CC*, Li SY. Significant Dry Weight Reduction after Transition from Peritoneal Dialysis to Hemodialysis. *Am J Nephrol*. 2025;56(4):412-420. (IF: 3.2)
13. ⁵Chen CY, Tsai MT, Lin NC, Lin CC*, Li SY. Laparoscopic-Assisted Seldinger Technique for Peritoneal Dialysis Catheter Insertion. *J Vis Exp*. 2025 May 23;(219). (IF: 1.0)
14. ²Chen FY, Lee CW, Chen YJ, Lin YH, Yeh CF, Lin CC*, Cheng HM. Pathophysiology and Blood Pressure Measurements of Hypertension in the Elderly. *J Formos Med Assoc*. 2025 Jul;124 Suppl 1:S10-S16. (IF: 2.5)
15. ^{2,5}Fu YT, Tseng CH, Huang WM, Yu WC, Cheng HM, Chiang CE, Chen CH, Sung SH, Lin CC*. Prognostic Impacts of Left Ventricular Strain in Hemodialytic Patients with Preserved Left Ventricular Systolic Function. *Sci Rep*. 2025 Jul 9;15(1):24723. (IF: 3.9)
16. ²Chien CY, Tsai MT, Chen JY, Chuang CL, Tian JY, Tai HL, Lin CC*, Li SY. Encapsulating Peritoneal Sclerosis Outcomes: A Retrospective Study on the Significance of Nutritional Parameter Variations. *BMC Nephrol*. 2025 Sep 1;26(1):509. (IF: 2.4)
17. ²Chen FY, Cheng WC, Kao ZK, Tan AC, Li SY, Yang CY, Lin H, Lin CC*. Optimizing Care for Chronic Kidney Disease: Considerations from A to Z. *J Chin Med Assoc*. 2025 Oct 1;88(10):738-746. (IF: 2.4)
18. ^{2,5}Chen HH*, Chen CH, Hou MC, ...Tseng WC, .. Chiou JF, Wu JY, Fann CSJ*. Population-specific polygenic risk scores for people of Han Chinese ancestry. *Nature* 2025;648:128-137. (IF: 48.5)
19. ²Chen YF, Fan CS, Hung YC, Chien PJ, Tsai WH, Yeh YT, Jhong JH, Hsieh YN, Huang YH, Jan MS, Chang CF, Yang CY*, Chang WW*. Heat-killed *Lacticaseibacillus paracasei* GMNL-346 exerts anti-oral cancer effect by suppressing cancer stem cell activity and rebalancing gut microbiota dysbiosis. *Int J Biol Macromol* 2025;334(Pt 1):149033. (IF: 8.5)
20. ^{2,5}Huang TH, Chen YC, Hsu YP, Yang CY*. Impacts of low body mass index on fusion surgery for osteoporotic vertebral compression fracture: A National Readmission Database analysis, 2016-2020. *World Neurosurg* 2025;203:124476. (IF: 2.1)
21. ²Huang JP, Wu HTH, Yang CY*. When rugger-jersey spine meets manubrial brown tumor. *Int Urol Nephrol* 2025; (Epub ahead of print). (IF: 1.9)
22. ^{1,5}Tsai CY, Wu TH, Ou SM, Lee HT, Shen CY, Lu CH, Tsai WH, Yu CL. The Pathogenesis, Potential Biomarkers and Novel Therapeutic Strategies for Tubulointerstitial Nephritis in Systemic Lupus Erythematosus-A Narrative Review. *Int J Mol Sci*. 2025 Nov 10;26(22):10903. (IF: 4.9)
23. ^{3,5} Chou CL, Jayatissa NU, Kichula ET, Ou SM, Limbutara K, Knepper MA. Phosphoproteomic response to epidermal growth factor in native rat inner medullary collecting duct. *Am J Physiol Renal Physiol*. 2025 Jan 1;328(1):F29-F47. (IF: 3.4)

24. ¹Lai CC, Chang BCC, Hwang LC*. Presence of coronary artery disease in adults with newly detected diabetes mellitus. *BMC Cardiovasc. Disord.* 2025 Feb 3;25(1):76. (IF:2.3)
25. ^{2,5}Liu HB*, Abedini A, Ha EJ, Ma ZY, Sheng X, Dumoulin B, Qiu CX, Aranyi T, Li S, Dittrich N, Chen HC, Tao R, Tarng DC, Hsieh FJ, Chen SA, Yang SF, Lee MY, Kwok PY, Wu JY, Chen CH, Khan A, Limdi NA, Wei WQ, Walunas TL, Karlson EW, Kenny EE, Luo Y, Kottyan L, Connolly JJ, Jarvik GP, Weng C, Shang N, Cole JB, Mercader JM, Mandla R, Majarian TD, Florez JC, Haas ME, Lotta LA, Drivas TG, Vy HMT, Nadkarni GN, Wiley LK, Wilson MP, Gignoux CR, Rasheed H, Thomas LF, Asvold BO, Brumpton BM, Hallan SI, Hveem K, Zheng J, Hellwege JN, Zawistowski M, Zollner S, Franceschini N, Hu H, Zhou J, Kiryluk K, Ritchie MD, Palmer M, Edwards TL, Voight BF, Hung AM, Susztak*. Kidney multiome-based genetic scorecard reveals convergent coding and regulatory variants. *Science* 2025;387(6734):- (IF:45.8)
26. ²Tai YH, Ho Y, Chung MC, Cheng BC, Yang CY*, Lin CC, Hsu YH, Wu MS, Hung KY, Tarng DC. Reversing the decline in peritoneal dialysis prevalence: The 2023 peritoneal dialysis reimbursement initiative in Taiwan. *Perit. Dial. Int.* 2025;():-. (IF:3.7)
27. ^{2,5}Wang SC, Lin YT*, Yang CY*, Ting CK, Lin YP, Tarng DC*. Blood Pressure Discrepancy Between Arm and Finger as a Predictor of Intradialytic Hypotension: A Pilot Study. *Ther. Apher. Dial.* 2025;():-. (IF:1.2)
28. ^{2,5}Wei CY*, Wen MS, Cheng CK, Sheen YJ, Yao TC, Lee SL, Wu JY, Tsai MF, Li LH, Chen CH, Fann CSJ, Yang HC, Huang YT, Chen HH, Liu YM, Yeh EC, Peng YC, Wang SJ, Chen SP, Tsai MT, Huo TL, Su CW, Tarng DC, Huang CC, Fuh JL, Lan KH, Liu YT, Lu CL, Lee YC, Huang YH, Li CP, Wang YF, Hsieh YC, Chen YM, Hsiao TH, Lin CH, Chen YJ, Chen IC, Mao CL, Chang SJ, Chang YL, Liao YJ, Lai CH, Lee WJ, Tung H, Yen TT, Yen HC, Chang JH, Huang CY, Chan L, Lin YW, Hsiao BY, Hu CJ, Lin YK, Lin YF, Chang TC, Wu DC, Kan JY, Hsu CY, Chen SC, Li CC, Huang CF, Sheu CC, Yang LJ, Chen CH, Chen KM, Chang SM, Liou MS, Wang SP, Lin KT, Chuang HP, Chen YJ, Sin J, Chen YT, Chang CC, Kuo CF, Lin JC, Kuo HC, Chan TM, Lee CW, Lai JH, Luo SF, Cheng HT, Lin LY, Chang LC, Tsai CT, Kao HL, Yu JJ, Jeng JS, Chiu MC, Hong TC, Yang SF, Lu HJ, Su SC, Chu PL, Li PF, Tsai CL, Tsai CK, Tang SE, Lin CM, Wu YF, Huang CY, Ling SZ, Chang CC, Lin TK, Hsiao SM, Chang CH, Chen CD, Ma GC, Chang TY, Hwang JJ, Lu CL, Kao KJ, Hung CF, Chen SS, Chen PY, Tsui K, Chen YT, Chen CH, Chien CC, Chiang HS, Chiu YL, Chen HC, Kwok PY. Clinical impact of pharmacogenetic risk variants in a large chinese cohort. *Nat. Commun.* 2025;16(1):6344. (IF:15.7)

Hematology

1. ^{2,4}Chen CF*, Hsiao LT, Chiu JW, Tsai SW, Chen CM, Wu PK, Chen WM. Clinical features and surgical treatment of hemophilic pseudotumors: A single-center experience over a 20-year

- period. *J. Chin. Med. Assoc.* 2025;88(10):774-782. (IF:2.4)
2. ^{2,5}Lee JW, Jang JH*, Yamazaki H, Sawa M, Kizaki M, Tomiyama Y, Nagafuji K, Usuki K, Gau JP, Morita Y, Tang JL, Chang H, Noshiro M, Matsuda A, Ozawa K, Mitani K, Kanda Y, Nakao S. Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia. *Blood Adv.* 2025;9(22):5732-5735. (IF:7.1)
3. ²Lin TA, Lin YT, Liu CJ*. Cryptococcal antigen cross-reactivity is associated with fatal trichosporonosis in patients with hematologic diseases. *Eur. J. Clin. Microbiol. Infect. Dis.* 2025;44(12):2955-2964. (IF:3)
4. ^{2,5}Lin WY, Tsai CK, Yeh CM, Liu CJ*. Identifying risk factors for methotrexate-induced acute kidney injury despite full prevention in patients with primary central nervous system lymphoma. *Toxicol. Appl. Pharmacology.* 2025 Sep; 502:117436 (IF:3.4)
5. ²Liu YC*, Lin TA, Fan NW, Ko PS, Wang HY, Tsai CK, Chien SH, Liu CJ, Hsiao LT. Incidence and impact of invasive fungal infection comparing post-transplant cyclophosphamide with cyclosporine plus methotrexate GVHD prophylaxis in allogeneic HSCT. *J. Microbiol. Immunol. Infect.* 2025;58(2):226-232. (IF:3.7)
6. ^{2,5}Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trneny M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song YQ, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang YW, Mccall B, Chohan S, Sugidono M, Yan MR, Batlevi CL, Tilly H, Flowers CR*. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. *J. Clin. Oncol.* 2025;43(35):- (IF:43.4)
7. ^{2,5}Wu YX, Hu CW, Chang JY, Chen SW, Lin TA, Lin ECY, Chen MH, Yang CM, Lu HY, Teng CJ, Chang Y, I*. Impaired Cytokine Secretion Contributes to Age-Dependent Immune Dysfunction in SARS Coronavirus Response and Is Restored by Young CD11b-Positive Cell Transfer. *Aging Cell* 2025;24(9):- (IF:7.1)
8. ^{2,5}Zhao JH, Lin SY, Attias R, Mathews L, Engel C, Larghero G, Vremenko D, Kao TW, Lee TH, Wang YH, Tsai CC, Marostica E, Lo YC, Meredith D, Ligon KL, Arnaout O, Roetzer-Pejrimovsky T, Lin SC, Shih NN, Chaisuriya N, Cook DJ, Chiang JH, Liu CJ, Woehrer A, Golden JA, Nasrallah MP, Yu KH*. Uncertainty-aware ensemble of foundation models differentiates glioblastoma from its mimics. *Nat. Commun.* 2025;16(1):8341. (IF:15.7)

Allergy, Immunology and Rheumatology

1. ⁵Chen HH*, Chen CH, Hou MC, Fu YC, Li LH, Chou CY, Yeh EC, Tsai MF, Chen CH, Yang HC, Huang YT, Liu YM, Wei CY, Su JP, Lin WJ, Wang EHF, Chiang CL, Jiang JK, Lee IH, Liang KH, Chen WS, Tsai HC, Lin SY, Chang FP, Ho HL, Yeh YC, Tseng WC, Lin MH, Chang HT, Tseng LM, Liang WY, Chen PCH, Hsieh YC, Chen YM, Hsiao TH, Lin CH, Chen YJ, Chen IC, Mao CL, Chang SJ, Chang YL, Liao YJ, Lai CH, Lee WJ, Tung H, Yen TT, Yen HC,

- Chen MY, Lin YC, Kao YT, Kao BZ, Lee JE, Chung CL, Liu JC, Chan PL, Lin CH, Chen CH, Wu IC, Lin LC, Wang JW, Shih SL, Hsieh SW, Hung CH, Li WM, Yang CJ, Yang CS, Weng RH, Chen YC, Chang CP, Wu TH, Lin YC, Sheen YJ, Wang SH, Chen SP, Raben T, Widen E, Hsu SP, Hsieh FJ, Ho DR, Huang YH, Yang CH, Huang YS, Chen YF, Wu HM, Tsai PH, Huang KG, Chien CY, Ho YL, Wu MS, Kao JH, Liu YB, Juang MJ, Lin MH, Lin YH, Lee JY, Lu HJ, Lu CH, Feng AC, Liu JS, Chiang CP, Chu NF, Lin JC, Yeh YW, Meng E, Huang CY, Li CC, Wang TF, Su KY, Wang JK, Chen MH, Chen HF, Ma GC, Chang TY, Chiang FT, Chang HJ, Kao KJ, Hung CF, Tsai CY, Chen PY, Tsui KC, Chen YT, Kwok PY, Sheu WHH, Yang SF, Liou JM, Wang JY, Chiou JF, Wu JY, Fann CSJ*. Population-specific polygenic risk scores for people of Han Chinese ancestry. *Nature*. 2025;648(8092):128-137. (IF:48.5)
2. ⁵Chen L, Lin T, Chang Y, Hsu H, Shen Y, Lin S, Chen W, Hu L, Kuo P, Kuo T, Chen S, Chen J, Lien Y, Chang C*. Effect of TNF- α blockers on reducing the risk of dementia in rheumatoid arthritis: a nationwide cohort study. *Clin. Exp. Rheumatol*. 2025;43(5):931-938. (IF:3.3)
 3. ²Chen WS, Hsu HC, Lin TM, Chang YS, Lin YC, Kuo TT, Shen YC, Chen SC, Chen JH, Lee HY*, Chang CC*. Hydroxychloroquine dose-dependently reduces the risk of incident diabetes in primary Sjogren syndrome patients on glucocorticoids: a nationwide population-based cohort study. *Arthritis Res. Ther*. 2025;27(1):88. (IF:4.6)
 4. ²Chen WS, Lin TM, Chang YS, Shen YC, Hsu HC, Kuo TT, Chen SC, Chen JH, Chang CC*. Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas. *CTS-Clin. Transl. Sci*. 2025;18(3):e70177. (IF:2.8)
 5. ^{1,5}Huang CC, Wang CH, Yeh HY, Tsai HC, Yang CW, Li TH, Su CW, Yang YY*, Lin HC, Hou MC. Peroxisome Proliferator-Activated Receptor α /g and Cannabinoid Receptor 2 Agonist Attenuated Nonalcoholic Steatohepatitis Exosome-Related Abnormalities in Mice. *Am. J. Pathol*. 2025;195(2):188-203. (IF:3.6)
 6. ⁵Li TH, Huang YS, Ma CC, Tsai SY, Tsai HC, Yeh HY, Shen HC, Hong SY, Su CW, Yang H, Yang YY*, Hou MC. GCKR Polymorphisms Increase the Risks of Low Bone Mineral Density in Young and Non-Obese Patients With MASLD and Hyperuricemia. *Kaohsiung J. Med. Sci*. 2025;41(6):e70017. (IF:3.1)
 7. ⁵Li TH, Yeh HY, Lin SW, Huang YS, Zhuo ZW, Ma CC, Hsu TL, Wu WK, Tsai HC, Shen HC, Su CW, Yang YY*, Lin HC, Hou MC. Adenosine A2AR agonist blocks mesenteric lymphatic epithelium, adipose tissue and Treg cells links of metabolic dysfunction-associated steatotic liver disease mice. *Mol. Cell. Endocrinol*. 2025;610:112667. (IF:3.6)
 8. ¹Liao SY, Liao HT*. Pulmonary alveolar proteinosis in Sjogren's syndrome. *Joint Bone Spine* 2025;92(5):105937. (IF:4.3)
 9. ⁵Lien CY, Wang HJ, Lu CK, Hsu TH, Chu WC, Lai CC*. Deep Learning with an Attention Mechanism for Enhancing Automated Modified Total Sharp/van der Heijde Scoring of Hand X-ray Images in Rheumatoid Arthritis. *J. Med. Biol. Eng*. 2025;45(2):298-306. (IF:1.7)
 10. ⁵Liu FC, Lu CH, Kuo CF, Liao HT*, Lee SS, Su KY, Sung WY, Tsai WC, Chen HH, Chen HA, Wei JCC, Tseng JC, Weng MY, Chen HC*, Hsieh SC*. Clinical Response to Adalimumab Therapy and Its Determinants in Patients With Radiographic Axial Spondyloarthritis: A Prospective Real-World Study in Taiwan. *Int. J. Rheum. Dis*. 2025;28(6):e70285. (IF:2)
 11. ^{1,5}Shen HC, Tseng CH, Lin YH, Yeh HY, Tsai HC, Hong SY, Li TH, Su CW, Perng DW, Yang YY*, Hou MC. Protective effects of statins on pulmonary function in patients with persistent hyperlipidemia: a retrospective cohort study. *Ther. Adv. Respir. Dis*. 2025;19:17534666251320875. (IF:3)

12. ^{1,2}Tsai HC, Sun YS, Chen WS, Tsai WH, Huang DF, Yang YY, Liao HT*, Tsai CY*. Clinical and immunological differences between primary and autoimmune-associated neuromyelitis optica spectrum disorders: a retrospective study. *Lupus Sci. Med.* 2025;12(1):e001491. (IF:4)
13. ^{1,2}Tsao YP, Chen HH, Hsieh TY, Li KJ, Yu KH, Cheng TT, Tseng JC, Lu CC, Chen DY*. Evidence- and Consensus-Based Recommendations for the Screening, Diagnosis, and Management of Secondary Hypogammaglobulinemia in Patients With Systemic Autoimmune Rheumatic Diseases by the Taiwan College of Rheumatology Experts. *Int. J. Rheum. Dis.* 2025;28(6):e70310. (IF:2)
14. ^{1,2,5}Yeh HY, Pan MH, Huang CJ, Hong SY, Yang H, Yang YY*, Huang CC, Tsai HC, Li TH, Su CW, Hou MC. Triglyceride-glucose index and cancer risk: a prospective cohort study in Taiwan. *Diabetol. Metab. Syndr.* 2025;17(1):283. (IF:3.9)
15. ⁵Yen YN, Liao HT*. Coronary polyarteritis nodosa. *Lancet Rheumatol.* 2025;7(11):e823-e824. (IF:16.4)

Transfusion Medicine

1. ^{2,5}Liu YC, Lin TA, Fan NW, Ko PS, Wang HY, Tsai CK, Chien SH, Liu CJ, Hsiao LT. Incidence and impact of invasive fungal infection comparing post-transplant cyclophosphamide with cyclosporine plus methotrexate GVHD prophylaxis in allogeneic HSCT. *Journal of Microbiology Immunology and Infection.* 2025 Apr; 58(2):226-232. (IF: 3.7)
2. ^{2,5}Teng CJ, Yeh CM, Liu CJ, Chen TJ, Huang Nicole, Chou YJ. Pregnancy among thyroid cancer survivors: do thyroidectomy and radioactive iodine matter? *Postgraduate Medical Journal.* 2025 Jun; 101(1197):636-643. (IF: 2.7)
3. ^{2,5}Ho YC, Chang MC, Lin WY, Wu CY, Liu SY, Chuang C, Juan CH, Liu CJ, Lin YT*. Prognostic factors of disease progression in patients with mild-to-moderate COVID-19 on early remdesivir treatment in Taiwan. *Journal of Infection and Public Health.* 2025 May; 18(5):102705. (IF: 4.0)
4. ^{2,5}Lin WY, Tsai CK, Yeh CM, Liu CJ*. Identifying risk factors for methotrexate-induced acute kidney injury despite full prevention in patients with primary central nervous system lymphoma. *Toxicology and Applied Pharmacology.* 2025 Jun; 502:117436. (IF: 3.4)
5. ^{2,5}Zhao J, Lin SY, Attias R, Mathews L, Engel C, Larghero G, Vremenko D, Kao TW, Lee TH, Wang YH, Tsai CC, Marostica E, Lo YC, Meredith D, Ligon KL, Arnaout O, Roetzer-Pejrimovsky T, Lin SC, Shih NN, Chaisuriya N, Cook DJ, Chiang JH, Liu CJ, Woehrer A, Golden JA, Nasrallah MP, Yu KH. Uncertainty-Aware Ensemble of Foundation Models Differentiates Glioblastoma from its Mimics – A Multi-Center Study. *Nature Communications.* 2025 Sep; 16(1):8341. (IF: 15.7)
6. ^{2,4}Lin TA, Lin YT, Liu CJ*. Cryptococcal antigen cross-reactivity is associated with fatal trichosporonosis in patients with hematologic diseases. *European Journal of Clinical Microbiology & Infectious Diseases.* 2025 Dec; 44(12):2955-2964. (IF: 3.0)

7. ^{2,5}Yeh CM, Chou YJ, Lin SK, Liu CJ, Huang NCL*. Physician Partnerships and Adverse Outcomes among Breast Cancer Survivors: The Role of Adherence to Adjuvant Hormone Therapy. *Journal of General Internal Medicine*. 2025 Dec. (IF: 4.2)
8. ^{2,5}Huang CC, Yeh YC, Cheng HF, Chen BF, Liu CY, Tsai YF, Ho HL*, Tseng LM*. Comprehensive genomic profiling of Taiwanese triple-negative breast cancer with a large targeted sequencing panel. *J. Chin. Med. Assoc.* 2025;88(8):641-649. (IF:2.4)
9. ^{2,5}Lai KC, Hsu TL, Lin SY, Chiang NJ, Chen MH, Chao Y, Yang MH, Chen SC*. Real-world efficacy of cabozantinib alone or in combination with ICIs in heavily pretreated hepatocellular carcinoma: potential role of AXL and MET expression Cabozantinib ICIs in pretreated HCC patients. *Ann. Hepatol.* 2025 30(2):101917. (IF:4.4)

General Medicine

1. ^{2,4}Amadis MR, Lo LW, Salim S*, Yamin M, Lin YJ, Chang SL, Hu YF, Chung FP, Sukardi R, Lin CY, Chang TY, Kuo L, Pramudita A, Liu CM, Liu SH, Wu CI, Huang YS, Nguyen DSN, Tran DC, Chen SA. Multistep Algorithm to predict RVOT PVC site of origin for successful ablation using available criteria: A two-center cross-validation study. *Pacing Clin Electrophysiol* 2025;48(1):128-136. (IF: 1.3)
2. ^{2,4}Bautista JAL, Liu CM, Ibrahim AE, Lo LW*, Chung FP, Hu YF, Chang SL, Lin YJ, Lin CY, Chang TY, Kuo L, Liu SH, Cheng WH, Chen WT, Kao PH, Kuo MJ, Nguyen-Khac TC, Li GY, Lin CH, Huang YS, Wu SJ, Siow YK, Son Nguyen ND, Tran DC, Chen SA. Impact of proximity of left atrium to descending aorta on left inferior pulmonary vein triggers or drivers of atrial fibrillation: A risk score model. *Heart Rhythm* 2025;22(1):49-56. (IF: 5.8)
3. ^{2,4}Chien CY, Tsai MT, Chen JY, Chuang CL, Tian JY, Tai HL, Lin CC*, Li SY*. Encapsulating peritoneal sclerosis outcomes: a retrospective study on the significance of nutritional parameter variations. *BMC Nephrol* 2025;26(1):509. (IF: 2.4)
4. ^{2,4}Chang CL, Chang CC, Chuang CL, Hsu SJ*, Tsai MH*, Tsai CJ, Chang YY, Hou MC, Lee FY. The influences of antihistamine on liver fibrosis, vasoresponsiveness, and portosystemic shunting in bile duct-ligated cirrhotic rats. *J Chin Med Assoc* 2025;88(11):825-835 (IF: 2.4)
5. ²Ho CT, Tan ECH, Su CW*. Reply to “Insights on Risk Score Development: Considerations for Early-Stage Hepatocellular Carcinoma Models”. *Clin Mol Hepatol* 2025;31(1):e96-7 (IF: 16.9)
6. ²Ho CT, Tan ECH, Su CW*. Reply to “Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma”. *Clin Mol Hepatol* 2025;31(1):e101-2 (IF: 16.9)
7. ²Ho CT, Kao WY, Su CW*. The frontline of metabolic dysfunction-associated steatotic liver disease: More to be discovered. *J Chin Med Assoc* 2025;88(9):660-1 (IF: 2.4)
8. ^{2,4}Huang HC, Chang CL, Hsu SJ, Chang CC*, Chuang CL, Luo JC, Hou MC, Lee FY. Time-restricted feeding attenuates hepatic inflammation and enhances muscular endurance of biliary

- cirrhotic rats. *Life Sci* 2025;379:123856. (IF: 5.1)
9. ^{2,4}Huang KJ, Ho CT, Lee PC, Chen SC, Liu CA, Chou SC, Lee IC, Huang YH, Luo JC, Hou MC, Wu JC, Su CW*. PIVKA-II as a prognostic marker in hepatocellular carcinoma patients with normal serum alpha-fetoprotein levels. *J Chin Med Assoc* 2025;88(12):915-21 (IF: 2.4)
 10. ^{2,5}Huang CC, Wang CH, Yeh HY, Tsai HC, Yang CY, Li TH, Su CW, Yang YY*, Lin HC, Hou MC. Chronic PPAR α / γ and CB2R agonist treatments attenuated visceral adipose tissue (VAT)-derived extracellular vesicle-related VAT and intestinal abnormalities in NASH mice. *Am J Pathol* 2025;195:188-203 (IF: 3.6)
 11. ²Kuo MJ, Chang SL, Huang JL, Lin YJ, Hsieh YC, Lo LW, Hu YF, Chung FP, Li CH, Lin CY, Chang TY, Kuo L, Wu CI, Liu CM, Liu SH, Huang YS, Chen SA. Long-term outcome of lesion size index-guided high-power ablation with high-density mapping for pulmonary vein isolation in patients with paroxysmal atrial fibrillation. *J Arrhythm* 2025;41(4):e70127. (IF:1.7)
 12. ^{2,4}Kuo MJ, Lo LW*, Huang JL, Lin YJ, Hsieh YC, Chang SL, Hu YF, Chung FP, Li CH, Lin CY, Chang TY, Kuo L, Wu CI, Liu CM, Liu SH, Huang YS, Kim S, Chen SA. Application of peak frequency annotation after pulmonary vein isolation and its association with long-term atrial fibrillation recurrence. *Europace*. 2025;27(10):euaf233. (IF:7.5)
 13. ^{2,4}Lee PC, Cheng TY, Ho CT, Huang KW, Chau GY, Huang YH, Huo TI, Hou MC, Wu JC, Su CW*. Gender different impacts of muscle mass and adipose tissue on patients with hepatocellular carcinoma undergoing surgical resection. *Liver Int* 2025;45(2):e16237 (IF: 5.2)
 14. ^{2,4}Lee IC, Wang HW, Teng W, Lin TJ, Chen CH, Lai HC, Lee TY, Chang CW, Hung CH, Dai CY, Hung YP, Shen YC, Su CW, Ho MC, Lee WC, Chau GY, Ting CT, Liang PC, Liu CA, Chang PY, Chen KY, Lin SM, Chen LT, Huang YH*. Taiwan Liver Cancer Association management consensus guidelines for intermediate stage hepatocellular carcinoma. *Clin Mol Hepatol* 2025;31(4):1213-32 (IF: 16.9)
 15. ^{2,4}Li TH, Huang YS, Ma CC, Tsai SY, Tsai HC, Yeh HY, Shen HC, Hong SY, Su CW, Yang HI, Yang YY*, Hou MC. GCKR polymorphisms increase the risks of low bone mineral density in young and non-obese patients with MASLD and hyperuricemia. *Kaohsiung J Med Sci* 2025;41(6):e70017 (IF: 3.1)
 16. ^{2,4}Li TH, Yeh HY, Lin SW, Huang YS, Zhuo ZW, Ma CC, Hsu TL, Wu WK, Tsai HC, Shen HC, Su CW, Yang YY*, Lin HC, Hou MC. Adenosine A2AR agonist blocks mesenteric lymphatic epithelium, adipose tissue and Treg cells links of metabolic dysfunction-associated steatotic liver disease mice. *Mol Cell Endocrinol* 2025;610:112667 (IF: 3.6)
 17. ^{2,4}Ling LC, Chang TY*, Lin CY, Lin YJ, Hu YF, Chung FP, Lo LW, Tuan TC, Chao TF, Liao JN, Kuo L, Liu CM, Liu SH, Wu CI, Chan CH, Chen SA. Impact of Obesity Phenotypes on Efficacy and Safety of Catheter Ablation for Patients with Paroxysmal Atrial Fibrillation. *Acta Cardiol Sin* 2025;41(6):691-702. (IF:1.8)
 18. ²Lu CH, Chang CW, Chen SC, Kao WY, Ting WY, Lu CH, Chuang KI, Ni CF, Hsieh YY,

- Wu MS, Su CW, Chang CC, Wu CH*. Machine learning-based survival analysis for patients receiving lenvatinib for unresectable hepatocellular carcinoma. *J Hepatocell Carcino* 2025;12:2625-37(IF: 3.4)
19. ²Lu CH, Kao WY, Wu CH, Ting WY, Lu CH, Chuang KI, Ni CF, Hsieh YY, Wu MS, Su CW, Chen SC*. Predicting survival outcomes in patients with hepatocellular carcinoma receiving lenvatinib by using the Up7-ALBI score. *Liver Cancer* 2025;14(6):704-17 (SCI, IF: 9.1)
 20. ^{2,4}Ma TH, Chen YJ*, Ho CT, Lee PC, Yang TC, Huang HC, Huang YH, Chen MH, Luo JC, Hou MC, Wu JC, Su CW. The impact of esophagogastric varices on the outcomes of patients with cholangiocarcinoma. *Clin Transl Gastroenterol* 2025;16(12):e00930 (IF: 3.0)
 21. ^{2,5}Shen HC, Tseng CH, Lin YH, Yeh HY, Tsai HC, Hong SY, Li TH, Su CW, Perng DW, Yang YY*, Hou MC. Protective effects of statins on pulmonary function in patients with persistent hyperlipidemia: a retrospective cohort study. *Ther Adv Respir Dis* 2025;19:17534666251320875 (IF: 3.0)
 22. ²Teng W, Chang TT, Su CW, Xu JH, Hsu CC, Chang YC, Liu WC, Chiou YW, Chang YC, Liang YJ*, Wu JC*. The impact of single-nucleotide variants of hepatitis B virus and antiviral on liver cancer in gray zone patients. *J Biomed Sci* 2025;32(1),101. (IF: 12.1)
 23. ^{2,4}Tsai CT, Lu YW, Huang WC, Huang SS, Teng HI, Tsai YL, Lee WL, Lu TM*. Revascularization of coronary chronic total occlusion in patients with end stage renal disease. *Sci Rep* 2025;15(1):13472 (IF: 3.9)
 24. ^{2,4}Tseng CH, Jou BY, Shen HC*, Yeh HY, Hong SY, Lin YH, Tsai HC, Li TH, Su CW, Chou KT, Perng DW, Yang YY*, Hou MC. Increased risk of acute exacerbation in obstructive airway disease: the impact of metabolic dysfunction-associated steatotic liver disease and small airway dysfunction. *BMJ Open Respir Res* 2025;12(1):e003352. (IF: 3.4)
 25. ^{2,4}Tseng HT, Liu PO, Hsu CY, Huang YH, Su CW, Hou MC, Ho SY, Huo TI.* Differential prognostic impact of tumor burden score on hepatocellular carcinoma patients with variable physical performance status. *Dig Dis Sci* 2025;70(7):2496-505 (IF: 2.5)
 26. ²Wei CY*, Wen MS, Cheng CK, Sheen YJ, Yao TC, Lee SL, Wu JY, Tsai MF, Li LH, Chen CH, Fann CS, Yang HC, Huang YT, Chen HH, Liu YM, Yeh EC, Peng YC, Wang SJ, Chen SP, Tsai MT, Huo TI, Su CW, Tarng DC, Huang CC, Fuh JL, Lan KH, Liu YT, Lu CL, Lee YC, Huang YH, Li CP, Wang YF, Hsieh YC, Chen YM, Hsiao TH, Lin CH, Chen YJ, Chen IC, Mao CL, Chang SJ, Chang YL, Liao YJ, Lai CH, Lee WJ, Tung H, Yen TT, Yen HC, Chang JH, Huang CY, Chan L, Lin YW, Hsiao BY, Hu CJ, Lin YK, Lin YF, Chang TC, Wu DC, Kan JY, Hsu CY, Chen SC, Li CC, Huang CF, Sheu CC, Yang LJ, Chen CH, Chen KM, Chang SM, Liou MS, Wang SP, Lin KT, Chuang HP, Chen YJ, Sin J, Chen YT, Chang CC, Kuo CF, Lin JC, Kuo HC, Chan TM, Lee CW, Lai JH, Luo SF, Cheng HT, Lin LY, Chang LC, Tsai CT, Kao HL, Yu JJ, Jeng JS, Chiu MC, Hong TC, Yang SF, Lu HJ, Su SC, Chu P, Li PF, Tsai CL, Tsai CK, Tang SE, Lin CM, Wu YF, Huang CY, Ling SZ, Chang CC, Lin

- TK, Hsiao SM, Chang CH, Chen CD, Ma GC, Chang TY, Hwang JJ, Lu CL, Kao KJ, Hung CF, Chen SS, Chen PY, Tsui K, Chen YT, Chen CH, Chien CC, Chiang HS, Chiu YL, Chen HC, Kwok PY*. Clinical impact of pharmacogenetic risk variants in a large Chinese cohort. *Nat Commun* 2025;16(1):6344 (IF: 15.7)
27. ^{2,5}Yeh HY, Pan MH, Huang CJ, Hong SY, Yang HI*, Yang YY*, Huang CC, Tsai HC, Li TH, Su CW, Hou MC. Triglyceride-glucose index and cancer risk: a prospective cohort study in Taiwan. *Diabetol Metab Syndr* 2025;17(1):283 (IF: 3.9)
28. Huang KJ, Ho CT, Lee PC, Chen SC, Liu CA, Chou SC, Lee IC, Huang YH, Luo JC, Hou MC, Wu JC, Su CW. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma patients with normal serum alpha-fetoprotein levels. *J CHIN MED ASSOC.* 2025 DEC ;88(12) :915-921. (IF: 2.4)

Endoscopy Diagnosis and Treatment

1. ^{2,4}Chang CL, Chang CC, Chuang CL, Hsu SJ*, Tsai MH*, Tsai CJ, Chang YY, Hou MC, Lee FY. The influences of antihistamine on liver fibrosis, vasoresponsiveness, and portosystemic shunting in bile duct-ligated cirrhotic rats. *J. Chin. Med. Assoc.* 2025;88(11):825-835. (IF:2.4)
2. ^{2,5}Deng FS, Lin MH, Huang CL, Wu CC*, Lu CL, Tsai YC*. Effects of *Lactococcus cremoris* PS133 in 5-Hydroxytryptophan-Induced Irritable Bowel Syndrome Model Rats. *Int. J. Mol. Sci.* 2025;26(6):- (IF:4.9)
3. ²Huang HC, Chang CL, Hsu SJ, Chang CC*, Chuang CL, Luo JC, Hou MC, Lee FY. Time-restricted feeding attenuates hepatic inflammation and enhances muscular endurance of biliary cirrhotic rats. *Life Sci.* 2025;379():-. (IF:5.1)
4. ²Lin KL, Lin WY, Wang YP*, Luo JC, Hou MC, Lang HC, Lu CL*. Epidemiology and practice patterns of achalasia in Taiwan: A nationwide population-based cohort study. *J. Chin. Med. Assoc.* 2025;88(5):383-388. (IF:2.4)
5. ^{2,5}Lin YZ, Chang JS, Chen WC, Jiang JK, Chang SC, Lan YT*. Endoscopic submucosal dissection as an alternative management for huge colon lipoma with acute intussusception. *Endoscopy* 2025;57(S 01):E461-E462. (IF:12.8)
6. ²Wu PS, Lee PC, Chang TE, Hsieh YC, Huang CW, Lin CH, Huang YL, Lin YT, Huo TI, Schnabl B, Lee KC*, Hou MC*. Fecal carriage of multidrug-resistant organisms increases the risk of hepatic encephalopathy in patients with cirrhosis: insights from gut microbiota and metabolite features. *Gut Pathogens* 2025;17(1):- (IF:4)
7. ²Huang HC*. Repurposing antihistamines beyond allergy control: Emerging therapeutic potentials in liver cirrhosis. *J Chin Med Assoc.* 2025 Dec 1;88(12):897-898. doi: 10.1097 (IF:2.4)

Holistic and Multidisciplinary Medicine

1. ²Chang CL, Chang CC, Chuang CL, Hsu SJ*, Tsai MH*, Tsai CJ, Chang YY, Hou MC, Lee FY. The influences of antihistamine on liver fibrosis, vasoresponsiveness, and portosystemic shunting in bile duct-ligated cirrhotic rats. *J. Chin. Med. Assoc.* 2025;88(11):825-835. (IF:2.4)
2. ²Hsu CH, Hsuan YT, Chan YJ, Chen HP*. Clinical presentation of cytomegalovirus meningoencephalitis: a retrospective study of 12 adult patients with a variety of immunocompromised conditions. *BMC Infect. Dis.* 2025;25(1):- . (IF:3)
3. ²Hsuan YT, Hsu CH, Chen CY, Chan YJ, Chen HP*. Clinical characteristics and prognostic factors in patients with stool cytomegalovirus positivity. *J. Chin. Med. Assoc.* 2025;88(11):836-843. (IF:2.4)
4. ²Huang HC, Chang CL, Hsu SJ, Chang CC*, Chuang CL, Luo JC, Hou MC, Lee FY. Time-restricted feeding attenuates hepatic inflammation and enhances muscular endurance of biliary cirrhotic rats. *Life Sci.* 2025;379():-. (IF:5.1)
5. ²Tsao YP, Chen HH, Hsieh TY, Li KJ, Yu KH, Cheng TT, Tseng JC, Lu CC, Chen DY*. Evidence- and Consensus-Based Recommendations for the Screening, Diagnosis, and Management of Secondary Hypogammaglobulinemia in Patients With Systemic Autoimmune Rheumatic Diseases by the Taiwan College of Rheumatology Experts. *Int. J. Rheum. Dis.* 2025 Jun;28(6):e70310. (IF:2)
6. ¹Chen LC, Kao ZK, Yang CY, Tarn DC. Urine Albumin-creatinine Ratio Accurately Reflects Daily Albuminuria in Nonobese Patients but Requires Body Weight Correction in Obese. *J Ren Nutr.* 2025 Sep;35(5):607-615. (IF: 3.2)
7. ¹Ko FS1, Wu TH, Su GY, Lin YH, Juan CC, Hwu CM*. Blood Cell Count-Based Inflammatory Markers Exhibit Superior Association with Diabetic Peripheral Neuropathy Compared to Protein-Based Markers. *J Inflamm Res.* 2025 Aug 7;18:10609-10617. (IF: 4.2)
8. ¹Ching-Hao Hsu ,Yi-Tien Hsuan , Yu-Jiun Chan, Hsin-Pai Chen. Clinical presentation of cytomegalovirus meningoencephalitis: a retrospective study of 12 adult patients with a variety of immunocompromised conditions. *BMC Infect Dis.* 2025 Apr 22;25(1):575. doi: 10.1186/s12879-025-10957-9..(IF: 3.0)